<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2210200239
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ferasiro 90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFERASIROX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        525.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FERASIRO contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools.</p><p><strong>&nbsp;</strong></p><p><strong>What FERASIRO is used for</strong></p><p>Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions.&nbsp;</p><p>In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage. Deferasirox is an iron chelator that combines with iron in the blood.</p><p>&nbsp;</p><p>FERASIRO is used to remove excess iron from the body in patients who have had too many blood transfusions in patients with beta thalassaemia major aged 2 years and older. It is also used in patients aged 10 years or older with non-transfusion dependent thalassemia syndromes.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take FERASIRO</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, tell your doctor before taking FERASIRO. If you think you may be allergic, ask your doctor for advice.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you have moderate or severe kidney disease.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you are currently taking any other iron chelator medicines.</p><p>&nbsp;</p><p><strong>FERASIRO is not recommended</strong></p><p>- if you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking FERASIRO:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you have a kidney or liver problem.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you have a cardiac problem due to iron overload.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you notice a marked decrease in your urine output (sign of kidney problem).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you vomit blood and/or have black stools.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you experience frequent abdominal pain, particularly after eating or taking FERASIRO.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you experience frequent heartburn.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you have a low level of platelets or white blood cells in your blood test.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you have blurred vision</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->if you have diarrhoea or vomiting.</p><p>If any of these apply to you, tell your doctor straight away.</p><p><strong>&nbsp;</strong></p><p><strong>Monitoring your FERASIRO treatment</strong></p><p>You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well FERASIRO is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant&nbsp;kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of FERASIRO most suitable for you and will also use these tests to decide when you should stop taking FERASIRO.</p><p>Your eyesight and hearing will be tested each year during treatment as a precautionary measure.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and FERASIRO</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>This includes in particular:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->other iron chelators, which must not be taken with FERASIRO,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as FERASIRO,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->simvastatin (used to lower cholesterol),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->oral bisphosphonates (used to treat osteoporosis),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->anticoagulant medicines (used to prevent or treat blood clotting),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->hormonal contraceptive agents (birth control medicines),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->bepridil, ergotamine (used for heart problems and migraines),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->repaglinide (used to treat diabetes),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->rifampicin (used to treat tuberculosis),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->phenytoin, phenobarbital, carbamazepine (used to treat epilepsy),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->ritonavir (used in the treatment of HIV infection),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->paclitaxel (used in cancer treatment),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->theophylline (used to treat respiratory diseases such as asthma),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->clozapine (used to treat psychiatric disorders such as schizophrenia),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->tizanidine (used as a muscle relaxant),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->cholestyramine (used to lower cholesterol levels in the blood),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant).</p><p>Additional tests may be required to monitor the blood levels of some of these medicines.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Older people (age 65 years and over)</strong></p><p>FERASIRO can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients.</p><p>They should be monitored closely by their doctor for side effects that may require a dose adjustment.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>FERASIRO can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose.</p><p>FERASIRO is not recommended for children aged under 2 years.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>FERASIRO is not recommended during pregnancy unless clearly necessary.</p><p>&nbsp;</p><p>If you are currently using an oral contraceptive or using a patch contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as FERASIRO may reduce the effectiveness of oral and patch contraceptives.</p><p>&nbsp;</p><p>Breast-feeding is not recommended during treatment with FERASIRO.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>If you feel dizzy after taking FERASIRO, do not drive or operate any tools or machines until you are feeling normal again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with FERASIRO will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>How much FERASIRO to take</strong></p><p>The dose of FERASIRO is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The usual daily dose for FERASIRO film-coated tablets at the start of the treatment for patients receiving regular blood transfusions is 14 mg per kilogram body weight. A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The usual daily dose for FERASIRO film-coated tablets at the start of the treatment for patients not receiving regular blood transfusions is 7 mg per kilogram body weight.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The maximum recommended daily dose for FERASIRO film-coated tablets is:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->28 mg per kilogram body weight for patients receiving regular blood transfusions,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->14 mg per kilogram body weight for adult patients not receiving regular blood transfusions,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.</p><p>&nbsp;</p><p><strong>When to take FERASIRO</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Take FERASIRO once a day, every day, at about the same time each day with some water.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Take FERASIRO film-coated tablets either on an empty stomach or with a light meal.</p><p>Taking FERASIRO at the same time each day will also help you remember when to take your tablets.</p><p>For patients who are unable to swallow whole tablets, FERASIRO film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple). The food should be immediately and completely consumed. Do not store it for future use.</p><p><strong>&nbsp;</strong></p><p><strong>How long to take FERASIRO</strong></p><p>Continue taking FERASIRO every day for as long as your doctor tells you. This is a long-term</p><p>treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: &ldquo;Monitoring your FERASIRO treatment&rdquo;).</p><p>&nbsp;</p><p><strong>If you have questions about how long to take FERASIRO, talk to your doctor.</strong></p><p>If you take more FERASIRO than you should If you have taken too much FERASIRO, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show them the pack of tablets. Medical treatment may be necessary.</p><p>&nbsp;</p><p><strong>If you forget to take FERASIRO</strong></p><p>If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).</p><p>&nbsp;</p><p><strong>If you stop taking FERASIRO</strong></p><p>Do not stop taking FERASIRO unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section &ldquo;How long to take FERASIRO&rdquo;).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could be serious and need immediate medical attention.</strong></p><p><em>These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people).</em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience a combination of any of the following symptoms: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged lymph nodes, (signs of severe skin reactions),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you notice a marked decrease in your urine output (sign of kidney problem),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience difficulty thinking, remembering information, or solving problems, being less alert or aware or feeling very sleepy with low energy (signs of a high level of ammonia in your blood, which may be associated with liver or renal problems and lead to a change in your brain function),</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you vomit blood and/or have black stools,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience frequent abdominal pain, particularly after eating or taking FERASIRO,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience frequent heartburn,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience partial loss of vision,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you experience severe upper stomach pain (pancreatitis),</p><p><strong>stop taking this medicine and tell your doctor straight away.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could become serious.</strong></p><p><em>These side effects are uncommon.</em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you get blurred or cloudy eyesight,</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If you get reduced hearing,</p><p><strong>tell your doctor as soon as possible.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other side effects</strong></p><p><em>Very common (may affect more than 1 in 10 people)</em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Disturbance in kidney function tests.</p><p><strong>&nbsp;</strong></p><p><em>Common (may affect up to 1 in 10 people)</em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating, constipation, indigestion</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Rash</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Headache</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Disturbance in liver function tests</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Itching</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Disturbance in urine test (protein in the urine)</p><p><strong>If any of these affects you severely, tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><em>Uncommon (may affect up to 1 in 100 people)</em></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Dizziness</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Fever</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Sore throat</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Swelling of arms or legs</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Change in the colour of the skin</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Anxiety</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Sleep disorder</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Tiredness</p><p><strong>If any of these affects you severely, tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Frequency not known&nbsp;</strong>(cannot be estimated from the available data).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated), in the number of white blood cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Hair loss</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Kidney stones</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Low urine output</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Tear in stomach or intestine wall that can be painful and cause nausea</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Severe upper stomach pain (pancreatitis)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Abnormal level of acid in blood</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Do not store above 30<sup>o</sup>&nbsp;C. Keep this medicine out of the sight and reach of children.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.<br />The expiry date refers to the last day of that month.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Do not use any pack that is damaged or shows signs of tampering.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance is deferasirox.</strong></p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Each film-coated tablet of&nbsp;FERASIRO 90 mg contains 90 mg deferasirox.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Each film-coated tablet of FERASIRO 180 mg contains 180 mg deferasirox.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Each film-coated tablet of FERASIRO 360 mg contains 360 mg deferasirox.</p><p><strong>The other ingredients are</strong>- Microcrystalline Cellulose (Avicel PH 102), Croscaramellose Sodium (Ac-Di-Sol), Low-substituted Hydroxypropyl cellulose, Poloxamer 188, Povidone K 30, Lactose Monohydrate, Colloidal Silicon Dioxide, Sodium stearyl fumarate, Hydrogenated Castor oil, Opadry Yellow 03H520019.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FERASIRO is supplied as film-coated tablets. 

-	FERASIRO 90 mg film-coated tablets are yellow colored, film coated oval, biconvex tablets with beveled edges debossed with 'D' on one side and '90' on another side.
-	FERASIRO 180 mg film-coated tablets are yellow colored, film coated oval, biconvex tablets with beveled edges debossed with 'D' on one side and '180' on another side.
-	FERASIRO 180 mg film-coated tablets are yellow colored, film coated oval, biconvex tablets with beveled edges debossed with 'D' on one side and '180' on another side.

10 Tablets of FERASIRO are sealed with Plain Lid Coated Aluminium Foil on one side and clear PVC/PE/PVdC film on another side in the form of a Alu-PVC/PE/PVdC blister pack and such 3 blisters are further packed in printed carton.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH and Secondary packaging:</p><p>Boston Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p>Full Manufacturing and Primary Packaging:</p><p>MSN Laboratories Private Limited</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو فيراسيرو</strong></p><p dir="RTL">يحتوي&nbsp;<strong>فيراسيرو</strong>&nbsp;على مادة فعالة تسمى ديفيراسيروكس. وهي عبارة عن دواء خالب للحديد يُستخدم لإزالة الحديد الزائد من الجسم (يُسمى أيضاً الحِمل الزائد للحديد). إنه يحبس ويزيل الحديد الزائد الذي يفرز بعد ذلك بشكل رئيسي في البراز.</p><p dir="RTL"><strong>لأجل ماذا يُستخدم فيراسيرو&nbsp;</strong></p><p dir="RTL">قد يكون تكرار نقل الدم ضرورياً لدى المرضى الذين يعانون أنواعاً مختلفة من فقر الدم (مثل الثلاسيميا, مرض الخلايا المنجلية أو متلازمات خلل التنسج النقوي&nbsp;MDS). مع ذلك، يمكن أن يسبب نقل الدم المتكرر تراكم حديد زائد. ذلك لأن الدم يحتوي على الحديد وأن جسمك ليس لديه طريقة طبيعية لإزالة الحديد الزائد الذي تحصل عليه جراء عمليات نقل دمك.</p><p dir="RTL">ولدى المرضى الذين يعانون من متلازمات الثلاسيميا غير المعتمدة على نقل الدم، قد يتطور مع مرور الزمن أيضاً حِمل الحديد الزائد، يعود على الأغلب إلى زيادة امتصاص الحديد الغذائي استجابة لانخفاض عدد خلايا الدم. ومع مرور الزمن، يمكن للحديد الزائد أن يضر بأعضاء هامة مثل الكبد والقلب. وتُستخدم الأدوية التي تُسمى خالبة للحديد لإزالة الحديد الزائد وتخفيف خطره الذي يتسبب في تلف الأعضاء.&nbsp;ديفيراسيروكس هو خالب للحديد حيث يتحد مع الحديد في الدم.</p><p dir="RTL">يُستخدم&nbsp;<strong>فيراسيرو</strong>&nbsp;لإزالة الحديد الزائد من الجسم&nbsp;لدى&nbsp;المرضى الذين أجروا عمليات نقل دم كثيرة جداً ولدى المرضى الذين يعانون من بيتا ثالاسيميا الكبيرة بعمر 2 سنة فأكبر. كما يُستخدم أيضاً لدى المرضى بعمر 10 سنة أو أكبر ممن يعانون من متلازمات الثلاسيميا غير المعتمدة على نقل الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ فيراسيرو</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه ديفيراسيروكس أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6). إذا كان ذلك ينطبق عليك، أخبر طبيبك قبل أخذ&nbsp;<strong>فيراسيرو</strong>. إذا كنت تعتقد أن لديك حساسية، اسأل طبيبك للحصول على المشورة.</p><p dir="RTL">- إذا كان لديك مرض كلوي متوسط ​​أو شديد.</p><p dir="RTL">- إذا كنت تتناول حالياً أي أدوية أخرى خالبة للحديد.</p><p dir="RTL">لا يوصى باستخدام&nbsp;<strong>فيراسيرو</strong></p><p dir="RTL">- إذا كنت بمرحلة متقدمة من متلازمة خلل التنسج النخاعي (MDS؛ انخفاض إنتاج خلايا الدم بواسطة نخاع العظام) أو كنت مصاباً بسرطان متقدم.</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول&nbsp;<strong>فيراسيرو</strong>:</p><p dir="RTL">- إذا كان لديك مشكلة في الكلى أو الكبد.</p><p dir="RTL">- إذا كان لديك مشكلة قلبية بسبب زيادة الحديد.</p><p dir="RTL">- إذا لاحظت انخفاضاً ملحوظاً في كمية البول (هذه علامة على مشكلة كلوية).</p><p dir="RTL">- إذا كنت تعاني من طفح جلدي حاد، أو صعوبة في التنفس ودوخة أو تورم بشكل رئيسي في الوجه والحلق (هذه علامات حساسية شديدة، انظر القسم 4 &quot;<strong>آثار جانبية محتملة</strong>&quot;).</p><p dir="RTL">- إذا واجهت خليطاً من أيٍّ من الأعراض التالية: طفح جلدي، جلد أحمر، تقرحات في الشفاه, العينين أو الفم، تقشير جلد، ارتفاع حرارة، أعراض شبيهة بالإنفلونزا، تضخم الغدد الليمفاوية (هذه علامات رد فعل جلدي شديد، انظر أيضاً القسم 4 &quot;<strong>آثار جانبية محتملة</strong>&quot;).</p><p dir="RTL">- إذا واجهت خليطاً من نعاس، ألم في أعلى البطن الأيمن, إصفرار أو زيادة إصفرار جلدك أو عينيك مع بول داكن (هذه علامات مشاكل في الكبد).</p><p dir="RTL">- إذا واجهت صعوبة في التفكير، تذكُّر المعلومات، أو حلّ المشكلات، كونك قليل الانتباه والإدراك أو الشعور بنعاس شديد مع انخفاض الطاقة (هذه علامات ارتفاع مستوى الأمونيا في دمك، ربما قد ترتبط بمشاكل في الكبد أو الكلى، انظر أيضاً القسم 4 &quot;<strong>آثار جانبية محتملة</strong>&quot;).</p><p dir="RTL">- إذا تقيأت دماً و/أو كان لديك براز أسود.</p><p dir="RTL">- إذا واجهت آلام متكررة في البطن، خاصة بعد الأكل أو بعد تناول&nbsp;<strong>فيراسيرو</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">- إذا كنت تعاني من حرقة متكررة.</p><p dir="RTL">- إذا كان لديك مستوى منخفض من الصفائح الدموية أو خلايا الدم البيضاء في اختبار دمك.</p><p dir="RTL">- إذا كان لديك عدم وضوح رؤية.</p><p dir="RTL">- إذا كان لديك إسهال أو قيء.</p><p dir="RTL">إذا كان أيٍّ من ذلك ينطبق عليك، أخبر طبيبك على الفور.</p><p dir="RTL"><strong>مراقبة معالجتك بدواء فيراسيرو</strong></p><p dir="RTL">سيكون لديك اختبارات دم وبول بانتظام أثناء المعالجة. وستراقب هذه كمية الحديد في جسمك (مستوى الدم من الفيريتين) لمعرفة مدى فعالية&nbsp;<strong>فيراسيرو</strong>. وستقوم الاختبارات أيضًا بمراقبة وظائف الكلى (مستوى كرياتينين الدم، وجود البروتين في البول) ووظيفة الكبد (مستوى الدم في الترانساميناز). قد يطلب منك طبيبك إجراء خزعة في الكلى، إذا هو/هي اشتبه بتلف كبدي ذو أهمية. وقد يجب عليك أيضاً عمل اختبارات&nbsp;(MRI)&nbsp;(التصوير بالرنين المغناطيسي) لتحديد كمية الحديد في الكبد. وسينظر طبيبك في هذه الاختبارات عند اتخاذ قراره بشأن جرعة&nbsp;<strong>فيراسيرو</strong>&nbsp;الأنسب لك وسيستخدم أيضاً هذه الاختبارات لتحديد متى يجب عليك التوقف عن تناول&nbsp;<strong>فيراسيرو</strong>. سيتم اختبار بصرك وسمعك كل سنة أثناء المعالجة كإجراء وقائي.</p><p dir="RTL"><strong>أدوية أخرى و فيراسيرو</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو أخذتَ مؤخراً أو قد تأخذ أية أدوية أخرى.</p><p dir="RTL">ويشمل ذلك بوجه الخصوص:</p><p dir="RTL">- أدوية أخرى خالبة للحديد, التي يجب ألا تؤخذ مع&nbsp;<strong>فيراسيرو</strong>,</p><p dir="RTL">- مضادات الحموضة (أدوية تُستخدم لمعالجة الحرقة) الحاوية على الألمنيوم، والتي لا ينبغي أن تؤخذ بنفس الوقت من اليوم مثل&nbsp;<strong>فيراسيرو</strong>،</p><p dir="RTL">- سايكلوسبورين (يُستخدم لمنع الجسم من رفض العضو المزروع أو لأجل حالات أخرى، مثل التهاب المفاصل الروماتوئيدي أو التهاب الجلد التأتبي)،</p><p dir="RTL">- سيمڤاستاتين (يُستخدم لخفض كوليسترول الدم)،</p><p dir="RTL">- بعض مسكنات الألم أو أدوية مضادة للالتهابات (مثل أسبرين, آيبوبروفين, ستيروئيدات قشرية)،</p><p dir="RTL">- بايفوسفونيت فموي (يُستخدم لعلاج هشاشة العظام)،</p><p dir="RTL">- أدوية مضادة للتخثر (تُستخدم لمنع أو معالجة تخثر الدم)،</p><p dir="RTL">- عوامل منع الحمل هورمونية (أدوية تحديد النسل)،</p><p dir="RTL">- بيبريديل، إرغوتامين (تُستخدم لمشاكل القلب والصداع النصفي)،</p><p dir="RTL">- ريباغلينيد (يُستخدم لمعالجة مرض السكري)،</p><p dir="RTL">- ريفامبيسين (يُستخدم لمعالجة السل)،</p><p dir="RTL">- فينيتوئين، فينوباربيتال، كاربامازيبين (تُستخدم لمعالجة الصرع) ،</p><p dir="RTL">- ريتوناڤير (يُستخدم لمعالجة عدوى فيروس نقص المناعة البشرية&nbsp;HIV)،</p><p dir="RTL">- باكليتاكسيل (يُستخدم لمعالجة السرطان)،</p><p dir="RTL">- ثيوفيللين (يُستخدم لمعالجة أمراض الجهاز التنفسي مثل الربو)،</p><p dir="RTL">- كلوزابين (يُستخدم لمعالجة الاضطرابات النفسية مثل انفصام الشخصية)،</p><p dir="RTL">- تيزانيدين (يُستخدم كمرخي عضلي)،</p><p dir="RTL">- كوليستيرامين (يُستخدم لخفض مستويات الكوليسترول في الدم)،</p><p dir="RTL">- بوسولفان (يُستخدم كعلاج قبل الزرع من أجل تدمير النخاع العظمي الأصلي قبل الزرع).</p><p dir="RTL">قد تتطلب الحالة إجراء اختبارات إضافية لمراقبة مستويات الدم لبعض هذه الأدوية.</p><p dir="RTL"><strong>كبار السن (65 سنة فما فوق)</strong></p><p dir="RTL">يمكن استخدام&nbsp;&nbsp;<strong>فيراسيرو</strong>&nbsp;لدى أشخاص بعمر 65 سنة فأكثر بنفس جرعة البالغين الآخرين. قد يعاني المرضى المسنون تأثيراتٍ جانبيةٍ (بخاصةً منها الإسهال) أكثر من المرضى الأصغر سناً. يجب مراقبتهم عن كثب من قبل أطبائهم من أجل التأثيرات الجانبية التي تتطلب ضبط الجرعة.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يمكن استخدام&nbsp;<strong>فيراسيرو</strong>&nbsp;لدى الأطفال والمراهقين الذين يتلقون عمليات نقل دم منتظمة وأعمارهم 2 سنة فأكثر ولدى الأطفال والمراهقين الذين لا يتلقون عمليات نقل دم منتظمة وأعمارهم 10 سنوات فأكثر. فمع نمو المريض سيقوم الطبيب بتعديل الجرعة.</p><p dir="RTL">لا يوصى باستخدام&nbsp;<strong>فيراسيرو</strong>&nbsp;لدى الأطفال الذين تقل أعمارهم عن سنتين.</p><p dir="RTL"><strong>الحَمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعةً، تظنينَ أنكِ قد تكوني حاملاً أو تُخططينَ لإنجابِ طفلٍ، اسألي طبيبكِ للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">لا يُوصى باستخدام&nbsp;<strong>فيراسيرو</strong>&nbsp;أثناء الحمل إلا إذا كان ذلك ضرورياً بشكل جليٍّ.</p><p dir="RTL">إذا كنتِ تستخدمينَ حالياً موانع الحمل الفموية أو تستخدمينَ رقعات لمنع الحمل، يجب عليكِ استخدام نوع إضافي أو مختلف عن موانع الحمل (مثل العازل)، لأن&nbsp;<strong>فيراسيرو</strong>&nbsp;قد يقلل من فعالية موانع الحمل الفموية والرقعات المانعة للحمل.</p><p dir="RTL">لا ينصح بالرضاعة الطبيعية أثناء العلاج مع&nbsp;<strong>فيراسيرو</strong>.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">إذا شعرت بالدوار بعد تناول&nbsp;<strong>فيراسيرو</strong>، فلا تقود السيارة أو تقوم بتشغيل أية أدواتٍ أو آلاتٍ حتى تشعر بأنك طبيعي مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن المعالجة بدواء&nbsp;<strong>فيراسيرو</strong>&nbsp;ستكون بإشراف طبيب يتمتع بخبرة في معالجة حِمل الحديد الزائد الناجم عن نقل الدم.</p><p dir="RTL">خُذ دائماً هذا الدواء تماماً كما أخبرك طبيبك. تحقّق مع طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>ما الكمية التي تأخذها من فيراسيرو&nbsp;</strong></p><p dir="RTL">تتعلَّق جرعة&nbsp;<strong>فيراسيرو</strong>&nbsp;بوزن الجسم لجميع المرضى. سيحسب طبيبك الجرعة التي تحتاجها ويخبرك بعدد الأقراص التي تتناولها كل يوم.</p><p dir="RTL">- الجرعة اليومية المعتادة لأقراص&nbsp;<strong>فيراسيرو</strong>&nbsp;المغلفة بفلم عند بداية المعالجة لدى المرضى الذين يتلقون عمليات نقل دم منتظمة هي 14ملغ لكل كيلوغرام من وزن الجسم. إن أعلى أو</p><p dir="RTL">أخفض جرعة بدئية قد يوصي بها طبيبك بناءً على احتياجاتك الفردية في المعالجة.</p><p dir="RTL">- الجرعة اليومية المعتادة لأقراص&nbsp;<strong>فيراسيرو</strong>&nbsp;المغلفة بفلم عند بداية المعالجة لدى المرضى الذين لا يتلقون عمليات نقل دم منتظمة هي 7ملغ لكل كيلوغرام من وزن الجسم.</p><p dir="RTL">- اعتماداً على كيفية استجابتك للمعالجة، قد يقوم طبيبك فيما بعد بضبط علاجك لجرعة أعلى أو أقل.</p><p dir="RTL">- الحد الأقصى الموصى به للجرعة اليومية من أقراص&nbsp;<strong>فيراسيرو</strong>&nbsp;المغلفة بفلم&nbsp;&nbsp;هو:</p><p dir="RTL">- 28 ملغ لكل كيلوغرام من وزن الجسم للمرضى الذين يتلقون عمليات نقل دم منتظمة،</p><p dir="RTL">- 14 ملغ لكل كيلوغرام من وزن الجسم للمرضى البالغين الذين لا يتلقون عمليات نقل دم منتظمة،</p><p dir="RTL">- 7 ملغ لكل كيلوغرام من وزن الجسم للأطفال والمراهقين الذين لا يتلقون عمليات نقل دم منتظمة.</p><p dir="RTL">يأتي ديفيراسيروكس أيضاً كأقراص &quot;قابلة للحلّ&quot;. إذا قمت بالتبديل من أقراص قابلة للحلّ إلى هذه الأقراص المغلفة بفلم، فستحتاج إلى ضبط الجرعة.</p><p dir="RTL">متى تأخذ&nbsp;<strong>فيراسيرو</strong></p><p dir="RTL">- خُذ&nbsp;<strong>فيراسيرو</strong>مرةً واحدةً في اليوم، كلَّ يوم، تقريباً بنفس الوقت مع بعض الماء.</p><p dir="RTL">- خُذ أقراص&nbsp;<strong>فيراسيرو</strong>&nbsp;المغلفة بفلم إما على معدةٍ فارغةٍ أو مع وجبةٍ خفيفةٍ.</p><p dir="RTL">سيساعدك تناول&nbsp;<strong>فيراسيرو</strong>&nbsp;بنفس الوقت كلَّ يوم أيضاً على تذكُّر وقتَ تناولك للأقراص.</p><p dir="RTL">بالنسبة للمرضى الذين لا يستطيعون ابتلاع القرص كاملاً، قد يتم سحق أقراص&nbsp;<strong>فيراسيرو</strong>&nbsp;المغلفة بفلم وتُؤخذ بواسطة رش كامل الجرعة على طعام طريٍّ مثل اللبن أو صلصة التفاح (تفاح مهروس). يجب التهام الطعام على الفور وبشكل كامل. لا تحفظه للاستخدام في المستقبل.</p><p dir="RTL"><strong>إلى متى ستأخذ فيراسيرو</strong></p><p dir="RTL">استمر في تناول&nbsp;<strong>فيراسيرو</strong>&nbsp;كل يومٍ مثلما أخبرك طبيبك. هذا المعالجة طويلة الأمد, ربما تستمر لشهور أو لسنوات. سيقوم طبيبك بمراقبة حالتك بانتظام للتأكد من أن المعالجة تعطي التأثير المطلوب (انظر أيضاً القسم 2: &quot;<strong>مراقبة معالجتك بدواء فيراسيرو</strong>&quot;).</p><p dir="RTL"><strong>إذا كانت لديك أسئلة حول المدة التي ستأخذ فيها دواء فيراسيرو، تحدث إلى طبيبك.</strong></p><p dir="RTL">إذا أخذت&nbsp;<strong>فيراسيرو</strong>&nbsp;أكثر مما يجب، وإذا كنت قد أخذت كثيراً جداً من&nbsp;<strong>فيراسيرو</strong>, أو أن أحداً أخرَ قد أخذ أقراصك خطأً، اتصل بطبيبك أو المستشفى للحصول على المشورة فوراً. قدِّم لهم عبوة الأقراص. قد تكون المعالجة الطبية ضرورية.</p><p dir="RTL"><strong>إذا نسيت أن تأخذ فيراسيرو</strong></p><p dir="RTL">إذا فاتتك جرعة، خذها حالما تتذكَّرها بنفس ذلك اليوم. خُذ جرعتك التالية كما هو مقرر. لا تأخذ جرعة مضاعفة باليوم التالي لتعويض الأقراص المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول فيراسيرو</strong></p><p dir="RTL">لا تتوقف عن تناول&nbsp;<strong>فيراسيرو</strong>&nbsp;ما لم يُخبرك طبيبكَ بذلك. إذا توقفت عن تناوله، فلن يتم إزالة الحديد الزائد من جسمك (انظر أيضاً أعلاه قسم &quot;<strong>إلى متى ستأخذ فيراسيرو</strong>).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، ولو أنها لا تحصل لدى كل شخص. معظم التأثيرات الجانبية خفيفة إلى معتدلة وستختفي عموماً بعد بضعة أيام إلى بضعة أسابيع من المعالجة.</p><p dir="RTL"><strong>قد تكون بعض التأثيرات الجانبية خطيرة وتحتاج إلى عناية طبية فورية.</strong></p><p dir="RTL"><em>هذه التأثيرات الجانبية غير شائعة (قد تؤثر حتى في 1 من كل 100 شخص) أو نادرة (قد تؤثر حتى في 1 من 1000 شخص).</em></p><p dir="RTL">- إذا حصل معك طفح جلدي حاد، أو صعوبة في التنفس ودوخة أو تورم بشكل رئيسي في الوجه والحلق (هذه علامات رد فعل تحسسي شديد)،</p><p dir="RTL">- إذا واجهت خليطاً من أيٍّ من الأعراض التالية: طفح جلدي، جلد أحمر، تقرحات في الشفاه، العينين أو الفم، تقشير جلد، ارتفاع حرارة، أعراض شبيهة بالإنفلونزا، تضخم الغدد اللمفاوية، (هذه علامات ردود فعل جلدية شديدة)،</p><p dir="RTL">- إذا لاحظت انخفاضاً ملحوظاً في كمية بولك (هذه علامة على مشكلة كلوية)،</p><p dir="RTL">- إذا واجهت خليطاً&nbsp;&nbsp;من نعاس, ألم في أعلى البطن الأيمن، إصفرار أو زيادة إصفرار جلدك أو عينيك مع بول داكن (هذه علامات مشاكل في الكبد)،</p><p dir="RTL">- إذا واجهت صعوبة في التفكير، تذكُّر المعلومات، أو حلّ المشاكل، كونك قليل الانتباه والإدراك أو الشعور بنعاس شديد مع انخفاض النشاط (هذه علامات ارتفاع مستوى الأمونيا في دمك، ربما قد ترتبط بمشاكل في الكبد أو الكلى وتؤدي إلى تغيير في وظيفة دماغك)،</p><p dir="RTL">- إذا تقيأت دماً و/أو كان لديك براز أسود،</p><p dir="RTL">- إذا عانيت من ألم متكرر في البطن، خاصة بعد الطعام أو بعد تناول&nbsp;<strong>فيراسيرو</strong>،</p><p dir="RTL">- إذا كنت تعاني من حرقة متكررة،</p><p dir="RTL">- إذا واجهت فقدان جزئي في الرؤية،</p><p dir="RTL">- إذا واجهت أام شديد في أعلى المعدة (التهاب البنكرياس)،</p><p dir="RTL"><strong>توقَّف عن تناول هذا الدواء وأخبر طبيبك على الفور.</strong></p><p dir="RTL"><strong>بعض التأثيرات الجانبية يمكن أن تصبح خطيرة.</strong></p><p dir="RTL"><em>هذه التأثيرات الجانبية غير شائعة.</em></p><p dir="RTL">- إذا حصل معك رؤية غير واضحة أو غائمة,</p><p dir="RTL">- إذا حصل معك انخفاض في السمع,</p><p dir="RTL"><strong>أخبر طبيبك بأقرب وقت ممكن.</strong></p><p dir="RTL"><strong>تأثيرات جانبية أخرى</strong></p><p dir="RTL"><em>شائعة جداً (قد تؤثر في أكثر من 1 من كل 10 أشخاص)</em></p><p dir="RTL">- اضطراب في اختبارات وظائف الكلى.</p><p dir="RTL"><em>شائعة (قد تؤثر حتى في 1 من كل 10 أشخاص)</em></p><p dir="RTL">- اضطرابات الجهاز الهضمي، مثل غثيان, قيء, إسهال, آلام في البطن, انتفاخ, إمساك, عسر هضم,</p><p dir="RTL">- طفح جلدي,</p><p dir="RTL">- صداع راس,</p><p dir="RTL">- اضطراب في اختبارات وظائف الكبد,</p><p dir="RTL">- حكة,</p><p dir="RTL">- اضطراب في اختبار البول (بروتين في البول),</p><p dir="RTL"><strong>إذا كان أيٍّ من هذه قد أثرت عليك بشدة, أخبر طبيبك.</strong></p><p dir="RTL"><em>غير شائعة (قد تؤثر حتى في 1 من كل 100 شخص)</em></p><p dir="RTL">- دوخة,</p><p dir="RTL">- حمى,</p><p dir="RTL">- التهاب حلق,</p><p dir="RTL">- تورم الذراعين أو الساقين,</p><p dir="RTL">- تغير لون البشرة,</p><p dir="RTL">- قلق,</p><p dir="RTL">- اضطراب النوم,</p><p dir="RTL">- تعب,</p><p dir="RTL"><strong>إذا كان أيٍّ من هذه قد أثرت عليك بشدة, أخبر طبيبك.</strong></p><p dir="RTL"><strong>غير معروفة التكرار</strong>&nbsp;(لا يمكن تقديرها من البيانات المتاحة).</p><p dir="RTL">- انخفاض في عدد الخلايا المشاركة في تخثر الدم (نقص صفيحات)، في عدد خلايا الدم الحمراء (فقر دم متفاقم)، أو في عدد خلايا الدم البيضاء (قلة العدلات) أو في عدد جميع أنواع خلايا الدم (قلة الكريات الشاملة),</p><p dir="RTL">- تساقط الشعر,</p><p dir="RTL">- حصى الكلى,</p><p dir="RTL">- انخفاض ناتج البول,</p><p dir="RTL">- تمزق في المعدة أو جدار الأمعاء قد يكون مؤلماً ويسبب الغثيان,</p><p dir="RTL">- أام شديد في أعلى المعدة (التهاب البنكرياس),</p><p dir="RTL">- مستوى حمض غير طبيعي في الدم,</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- لا تحفظه بدرجة حرارة أعلى من 30&ordm; مئوية. احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على البليستر والعلبة بعد&nbsp;EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">- لا تستخدم أية عبوةٍ&nbsp;&nbsp;تالفة أو تظهر عليها علامات العبث.</p><p dir="RTL">- لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تُساعد على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي ديفيراسيروكس.</strong></p><p dir="RTL">- يحتوي كل قرص مغلف بفلم من&nbsp;<strong>فيراسيرو</strong>&nbsp;عيار 90 ملغ على 90 ملغ ديفيراسيروكس,</p><p dir="RTL">- يحتوي كل قرص مغلف بفلم من&nbsp;<strong>فيراسيرو</strong>&nbsp;عيار 180 ملغ على 180 ملغ ديفيراسيروكس,</p><p dir="RTL">- يحتوي كل قرص مغلف بفلم من&nbsp;<strong>فيراسيرو</strong>&nbsp;عيار 360 ملغ على 360 ملغ ديفيراسيروكس,</p><p dir="RTL">المكونات الأخرى هي: مايكروكريستالين السليلوز&nbsp;(Avicel PH 102), كروسكاراميللوز صوديوم&nbsp;(Ac-Di-Sol), سليلوز منخفض الهيدروكسي بروبيل, بولوكزامر 188, بوڤيدون ك 30, لاكتوز مونوهايدرات, كولويدال سيليكون دايوكسايد, صوديوم ستيأريل فيومارات, زيت الخروع المهدرج, أوبادري أصفر&nbsp;03H520019.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر&nbsp;<strong>فيراسيرو بشكل أقراص&nbsp;</strong>مغلفة بفلم.</p><p dir="RTL">-&nbsp;<strong>فيراسيرو&nbsp;</strong>90 ملغ أقراص مغلفة بفلم صفراء اللون, بيضاوية مغلفة بفلم, أقراص ثنائية التحدب ذات حواف مشطوفة ممهورة بالحرف&nbsp;&quot;D&quot;&nbsp;في جانب و بالرقم&nbsp;&quot;90&quot;&nbsp;في الجانب الآخر.</p><p dir="RTL">-&nbsp;<strong>فيراسيرو&nbsp;</strong>180 ملغ أقراص مغلفة بفلم صفراء اللون, بيضاوية مغلفة بفلم, أقراص ثنائية التحدب ذات حواف مشطوفة ممهورة بالحرف&nbsp;&quot;D&quot;&nbsp;في جانب و بالرقم&nbsp;&quot;180&quot;&nbsp;في الجانب الآخر.</p><p dir="RTL">-&nbsp;<strong>فيراسيرو&nbsp;</strong>360 ملغ أقراص مغلفة بفلم صفراء اللون, بيضاوية مغلفة بفلم, أقراص ثنائية التحدب ذات حواف مشطوفة ممهورة بالحرف&nbsp;&quot;D&quot;&nbsp;في جانب و بالرقم&nbsp;&quot;360&quot;&nbsp;في الجانب الآخر.</p><p dir="RTL">كل 10 أقراص من&nbsp;<strong>فيراسيرو</strong>&nbsp;مختومة برقاقة ألمنيوم مغلفة بغطاء عادي في جانب واحد وطبقة شفافة&nbsp;PVC/PE/PVdC&nbsp;في الجانب الآخر بشكل عبوة بليستر&nbsp;PVC/PE/PVdC&nbsp;&nbsp;وكل ثلاث بليسترات معبأة في علبة مطبوعة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ- مالك حقوق التسويق والتغليف الثانوي:</p><p dir="RTL">شركة بوستن انكولجي العربية</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL">ب- التصنيع الكامل والتغليف الأولي:</p><p dir="RTL">مختبرات إم إس إن الخاصة المحدودة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت مراجعة هذه النشرة آخر مرة في 09/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FERASIRO 90/180/360
Deferasirox tablets 90 mg, 180 mg and 360 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FERASIRO Tablets 90 mg
Each film-coated tablet contains deferasirox 90 mg
FERASIRO Tablets 180 mg
Each film-coated tablet contains deferasirox 180 mg
FERASIRO Tablets 360 mg
Each film-coated tablet contains deferasirox 360 mg
For the full list of excipients, see section 6.1.FERASIRO Tablets 90 mg
Each film-coated tablet contains deferasirox 90 mg

FERASIRO Tablets 180 mg
Each film-coated tablet contains deferasirox 180 mg
FERASIRO Tablets 360 mg
Each film-coated tablet contains deferasirox 360 mg
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
FERASIRO Tablets 90 mg
Yellow colored, film coated oval, biconvex tablets with beveled edges debossed with 'D' on one side and '90' on another side.
FERASIRO Tablets 180 mg
Yellow colored, film coated oval, biconvex tablets with beveled edges debossed with 'D' on one side and '180' on another side.
FERASIRO Tablets 360 mg
Yellow colored, film coated oval, biconvex tablets with beveled edges debossed with 'D' on one side and '360' on another side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload)<br />FERASIRO is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.</p><p>Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes<br />FERASIRO is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.</p><p>Limitations of Use</p><p>The safety and efficacy of FERASIRO when administered with other iron chelation therapy have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transfusional Iron Overload</p><p>FERASIRO&nbsp;therapy should only be considered when a patient has evidence of chronic transfusional iron overload. The evidence should include the transfusion of at least 100 mL/kg of packed red blood cells (e.g., at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg), and a serum ferritin consistently greater than 1000 mcg/L.</p><p>Prior to starting therapy, or increasing dose, evaluate:</p><ul><li>Serum ferritin level</li><li>Baseline renal function:</li><li>Obtain serum creatinine in duplicate (due to variations in measurements)</li><li>Calculate the estimated glomerular filtration rate (eGFR). Use a prediction equation appropriate for adult patients (e.g., CKD-EPI, MDRD method) and in pediatric patients</li><li>(e.g., Schwartz equations).</li><li>Obtain urinalyses and serum electrolytes to evaluate renal tubular function (see section&nbsp;4.2 and section 4.4).</li><li>&bull;&nbsp;Serum transaminases and bilirubin (see section 4.2 and section 4.4).</li><li>&bull;&nbsp;Baseline auditory and ophthalmic examinations (see section 4.4).</li></ul><p><strong>Initiating Therapy:</strong><br />The recommended initial dose of FERASIRO for patients 2 years of age and older with eGFR greater than 60 mL/min/1.73 m2&nbsp;is 14 mg per kg body weight orally, once daily. Calculate doses (mg per kg per day) to the nearest whole tablet or nearest whole sachet content for granules. Changes in weight of pediatric patients over time must be taken into account when calculating the dose.</p><p><strong>During Therapy:</strong></p><ul><li><p>Monitor serum ferritin monthly and adjust the dose of FERASIRO, if necessary, every 3</p></li><li><p>to 6 months based on serum ferritin trends.</p></li><li><p>Use the minimum effective dose to achieve a trend of decreasing ferritin.</p></li><li><p>Make dose adjustments in steps of 3.5 or 7 mg per kg and tailor adjustments to the</p><p>individual patient&rsquo;s response and therapeutic goals.</p></li><li><p>In patients not adequately controlled with doses of 21 mg per kg (e.g., serum ferritin levels</p><p>persistently above 2500 mcg/L and not showing a decreasing trend over time), doses of up to 28 mg per kg may be considered. Doses above 28 mg per kg are not recommended (see section 4.4).</p></li><li><p>Adjust dose based on serum ferritin levels</p><ul><li><p>If the serum ferritin falls below 1000 mcg/L at 2 consecutive visits, consider dose</p><p>reduction, especially if the FERASIRO dose is greater than 17.5 mg/kg/day (see</p><p>section 4.8).</p></li><li><p>If the serum ferritin falls below 500 mcg/L, interrupt FERASIRO therapy and</p><p>continue monthly monitoring.</p></li><li><p>Evaluate the need for ongoing chelation therapy for patients whose conditions no</p><p>longer require regular blood transfusions.</p></li><li><p>Use the minimum effective dose to maintain iron burden in the target range (see</p><p>section 4.4).</p></li></ul></li><li><p>Monitor blood counts, liver function, renal function and ferritin monthly (see section4.4)</p></li><li><p>Interrupt FERASIRO for pediatric patients who have acute illnesses, which can cause volume depletion, such as vomiting, diarrhea, or prolonged decreased oral intake, and&nbsp;function, when oral intake and volume status are normal (see section 4.2, section 4.4 and&nbsp;section 5).</p><p><strong>Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes</strong></p><p>FERASIRO therapy should only be considered when a patient with NTDT syndrome has an LIC of at least 5 mg Fe/g dw and a serum ferritin greater than 300 mcg/L.<br />Prior to starting therapy, obtain:</p></li><li>LIC by liver biopsy</li><li>Baseline renal function:<br />-&nbsp;Obtain serum creatinine in duplicate (due to variations in measurements)<br />- &nbsp;Calculate the estimated glomerular filtration rate (eGFR). Use a prediction equation appropriate for adult patients (e.g., CKD-EPI, MDRD method) and in pediatric patients (e.g., Schwartz equations).<br />- &nbsp;Obtain urinalyses and serum electrolytes to evaluate renal tubular function (see section 4.2 and section 4.4)</li><li>Serum transaminases and bilirubin (see section 4.2 and section 4.4)&nbsp;</li><li>Baseline auditory and ophthalmic examinations (see section 4.4)</li></ul><p>&nbsp;</p><p><strong>Initiating Therapy:</strong></p><ul><li><p>The recommended initial dose of FERASIRO for patients with eGFR greater than 60&nbsp;mL/min/1.73 m2&nbsp;is 7 mg per kg body weight orally once daily. Calculate doses (mg per kg&nbsp;per day) to the nearest whole tablet or nearest whole sachet content for granules.</p></li><li><p>If the baseline LIC is greater than 15 mg Fe/g dw, consider increasing the dose to 14&nbsp;mg/kg/day after 4 weeks.</p></li></ul><p>&nbsp;</p><p><strong>During Therapy:</strong></p><ul><li>Monitor serum ferritin monthly. Interrupt treatment when serum ferritin is less than 300 mcg/L and obtain an LIC to determine whether the LIC has fallen to less than 3 mg Fe/g&nbsp;dw.</li><li>Use the minimum effective dose to achieve a trend of decreasing ferritin.</li><li>Monitor LIC every 6 months.</li><li>After 6 months of therapy, if the LIC remains greater than 7 mg Fe/g dw, increase the dose of deferasirox to a maximum of 14 mg/kg/day. Do not exceed a maximum of 14 mg/kg/day.</li><li>If after 6 months of therapy, the LIC is 3 to 7 mg Fe/g dw, continue treatment with deferasirox at no more than 7 mg/kg/day.</li><li>When the LIC is less than 3 mg Fe/g dw, interrupt treatment with deferasirox and continue to monitor the LIC.</li><li>Monitor blood counts, liver function, renal function and ferritin monthly (see section 4.4). Increase monitoring frequency for pediatric patients who have acute illness, which can cause volume depletion, such as vomiting, diarrhea, or prolonged decreased oral intake. Consider dose interruption until oral intake and volume status are normal. (see section 4.2, section 4.4 and section 5)&nbsp;<br />Restart treatment when the LIC rises again to more than 5 mg Fe/g dw.</li></ul><p><strong>Administration</strong></p><p>Swallow FERASIRO tablets once daily with water or other liquids, preferably at the same time each day.<br />Take FERASIRO tablets on an empty stomach or with a light meal (contains less than 7% fat content and approximately 250 calories). Examples of light meals include 1 whole wheat English muffin, 1 packet jelly (0.5 ounces), and skim milk (8 fluid ounces) or a turkey sandwich (2 oz. turkey on whole wheat bread w/ lettuce, tomato, and 1 packet mustard). Do not take FERASIRO tablets with aluminum-containing antacid products (see section 4.5). For patients who have difficulty swallowing whole tablets, FERASIRO tablets may be crushed and mixed with soft foods (e.g., yogurt or applesauce) immediately prior to use and administered orally. Commercial crushers with serrated surfaces should be avoided for crushing a single 90 mg tablet. The dose should be immediately and completely consumed and not stored for future use.</p><p>For patients who are currently on chelation therapy with Deferasirox tablets for oral suspension and converting to Deferasirox (film-coated tablets), the dose should be about 30% lower, rounded to the nearest whole tablet. The table below provides additional information on dosing conversion to Deferasirox (film-coated tablets).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deferasirox&nbsp;Tablets&nbsp;for&nbsp;oral</p><p>suspension&nbsp;(white&nbsp;roundtablet)</p></td><td style="vertical-align:top"><p>Deferasirox Tablets</p><p>(film&nbsp;coated&nbsp;blue&nbsp;oval&nbsp;tablet)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Transfusion-Dependent&nbsp;Iron&nbsp;Overload</strong></p></td></tr><tr><td style="vertical-align:top"><p>Starting&nbsp;Dose</p></td><td style="vertical-align:top"><p>20&nbsp;mg/kg/day</p></td><td style="vertical-align:top"><p>14&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Titration&nbsp;Increments</p></td><td style="vertical-align:top"><p>5&ndash;10&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>3.5&ndash;7&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Maximum&nbsp;Dose</p></td><td style="vertical-align:top"><p>40&nbsp;mg/kg/day</p></td><td style="vertical-align:top"><p>28&nbsp;mg/kg/day</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Non-Transfusion-Dependent&nbsp;Thalassemia&nbsp;Syndromes</strong></p></td></tr><tr><td style="vertical-align:top"><p>Starting&nbsp;Dose</p></td><td style="vertical-align:top"><p>10&nbsp;mg/kg/day</p></td><td style="vertical-align:top"><p>7&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Titration&nbsp;Increments</p></td><td style="vertical-align:top"><p>5&ndash;10&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>3.5&ndash;7&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Maximum&nbsp;Dose</p></td><td style="vertical-align:top"><p>20&nbsp;mg/kg/day</p></td><td style="vertical-align:top"><p>14&nbsp;mg/kg/day</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Use&nbsp;in&nbsp;Patients&nbsp;with&nbsp;Baseline&nbsp;Hepatic&nbsp;or&nbsp;Renal&nbsp;Impairment</strong></p><p><em>Patients&nbsp;with&nbsp;Baseline&nbsp;Hepatic&nbsp;Impairment</em></p><p>Mild (Child-Pugh A) Hepatic Impairment: No dose adjustment is necessary. Moderate&nbsp;(Child-Pugh&nbsp;B)Hepatic&nbsp;Impairment:&nbsp;Reduce&nbsp;the&nbsp;starting&nbsp;dose&nbsp;by&nbsp;50%.</p><p>Severe (Child-Pugh C) Hepatic Impairment:&nbsp;Avoid&nbsp;FERASIRO tablets. (see section&nbsp;4.4)</p><p><em>Patients&nbsp;with&nbsp;Baseline&nbsp;Renal&nbsp;Impairment</em></p><p>Do not use FERASIRO in adult or pediatric patients with eGFR less than 40 mL/min/1.73 m<sup>2</sup>&nbsp;(see section 4.4)</p><p>For&nbsp;patients&nbsp;with&nbsp;renal&nbsp;impairment&nbsp;(eGFR 40-60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), reduce&nbsp;the&nbsp;starting dose by 50%.</p><p>Exercise caution in pediatric patients with eGFR between 40 and 60 mL/minute/1.73 m<sup>2</sup>. If treatment is needed, use the minimum effective dose and monitor renal function frequently. Individualize dose titration based on improvement in renal injury.</p><p>&nbsp;</p><p><strong><u>Dose&nbsp;Modifications&nbsp;for&nbsp;Decreases&nbsp;in&nbsp;Renal&nbsp;Function&nbsp;While&nbsp;on&nbsp;FERASIRO</u></strong></p><p>FERASIRO&nbsp;is contraindicated&nbsp;in patients with&nbsp;eGFR less than&nbsp;40 mL/minute/1.73 m<sup>2</sup>&nbsp;(see section 4.3).</p><p>For&nbsp;decreases&nbsp;in&nbsp;renal&nbsp;function&nbsp;while&nbsp;receiving&nbsp;FERASIRO (see&nbsp;section&nbsp;4.4),&nbsp;modify&nbsp;the&nbsp;dose as follows:</p><p>Transfusional&nbsp;Iron&nbsp;Overload</p><p><em>Adults:</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->If&nbsp;the&nbsp;serum&nbsp;creatinine&nbsp;increases&nbsp;by&nbsp;33%&nbsp;or&nbsp;more&nbsp;above&nbsp;the&nbsp;average&nbsp;baseline&nbsp;measurement, repeat the&nbsp;serumcreatinine&nbsp;within&nbsp;1&nbsp;week, and&nbsp;if still elevated&nbsp;by&nbsp;33% or more,&nbsp;reduce the dose by 7 mg per kg.</p><p><em>Pediatric&nbsp;Patients&nbsp;(ages&nbsp;2&nbsp;years&ndash;17&nbsp;years):</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Reduce&nbsp;the&nbsp;dose&nbsp;by&nbsp;7&nbsp;mg&nbsp;per&nbsp;kg&nbsp;if&nbsp;eGFR&nbsp;decreases&nbsp;by&nbsp;greater&nbsp;than&nbsp;33%&nbsp;below&nbsp;the&nbsp;average baseline measurement and repeat eGFR within 1 week</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Interrupt FERASIRO for acute illnesses, which can cause volume depletion, such as vomiting,&nbsp;diarrhea,&nbsp;orprolonged&nbsp;decreased&nbsp;oral&nbsp;intake,&nbsp;and&nbsp;monitor&nbsp;more&nbsp;frequently.</p><p>Resume therapy as appropriate, based on assessments of renal function, when oral intake and volume status are normal.</p><p>Avoid&nbsp;use&nbsp;of&nbsp;other nephrotoxic&nbsp;drugs&nbsp;(see&nbsp;section&nbsp;4.4).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->In the setting of decreased renal function, evaluate the risk benefit profile of continued FERASIRO&nbsp;use. Use&nbsp;theminimum&nbsp;effective&nbsp;FERASIRO&nbsp;dose&nbsp;and&nbsp;monitor renal&nbsp;function more frequently, by evaluating tubular and glomerular function. Titrate dosing based on renal injury. Consider dose reduction or interruption and less nephrotoxic therapies until improvement of renal function. If signs of renal tubular or glomerular injury occur in the presence&nbsp;of other&nbsp;risk&nbsp;factors&nbsp;such&nbsp;as&nbsp;volume&nbsp;depletion,&nbsp;reduce&nbsp;or&nbsp;interrupt&nbsp;FERASIRO&nbsp;to prevent severe and irreversible renal injury (see section 4.4).</p><p>&nbsp;</p><p><em>All&nbsp;Patients&nbsp;(regardless&nbsp;of&nbsp;age):</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Discontinue&nbsp;therapy&nbsp;for&nbsp;eGFR&nbsp;less&nbsp;than&nbsp;40&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>&nbsp;(see&nbsp;section&nbsp;4.3).</p><p>&nbsp;</p><p>Non-Transfusion-Dependent&nbsp;Thalassemia&nbsp;Syndromes</p><p><em>Adults:</em></p><p>If the serum creatinine increases by 33% or more above the average baseline measurement, repeat the serum creatinine within 1 week, and if still elevated by 33% or more, interrupt therapy if the dose is 3.5 mg per kg, or reduce by 50% if the dose is 7 or 14 mg per kg.</p><p><em>Pediatric&nbsp;Patients&nbsp;(ages&nbsp;10&nbsp;years&ndash;17&nbsp;years):</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Reduce&nbsp;the&nbsp;dose&nbsp;by&nbsp;3.5&nbsp;mg&nbsp;per&nbsp;kg&nbsp;if&nbsp;eGFR&nbsp;decreases&nbsp;by&nbsp;greater&nbsp;than&nbsp;33%&nbsp;below&nbsp;the&nbsp;average&nbsp;baseline measurement and repeat the eGFR within 1 week.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Increase monitoring frequency for pediatric patients who have acute illnesses, which can cause volume depletion, such as vomiting, diarrhea, or prolonged decreased oral intake. Consider dose interruption until oral intake and volume status are normal. Avoid use of other nephrotoxic drugs (see section 4.4).</p><p>In the setting of decreased renal function, evaluate the risk benefit profile of continued FERASIRO&nbsp;use. Use&nbsp;the&nbsp;minimumeffective&nbsp;FERASIRO&nbsp;dose&nbsp;and&nbsp;monitor renal&nbsp;function more frequently, by evaluating tubular and glomerular function. Titrate dosing based on renal injury. Consider dose reduction or interruption and less nephrotoxic therapies until&nbsp;presence&nbsp;of&nbsp;other&nbsp;risk&nbsp;factors&nbsp;such&nbsp;as&nbsp;volume&nbsp;depletion,&nbsp;reduce&nbsp;or&nbsp;interrupt&nbsp;FERASIRO&nbsp;to prevent severe and irreversible renal injury (see section 4.4).</p><p><em>All&nbsp;Patients&nbsp;(regardless&nbsp;of&nbsp;age):</em></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Discontinue&nbsp;therapy&nbsp;for&nbsp;eGFR&nbsp;less&nbsp;than&nbsp;40&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>&nbsp;(see&nbsp;section&nbsp;4.3).</p><p>&nbsp;</p><p><strong>Dose&nbsp;Modifications&nbsp;Based&nbsp;on&nbsp;Concomitant&nbsp;Medications</strong></p><p><em>UDP-glucuronosyltransferases&nbsp;(UGT)&nbsp;Inducers</em></p><p>Concomitant&nbsp;use&nbsp;of&nbsp;UGT&nbsp;inducers&nbsp;decreases&nbsp;systemic&nbsp;exposure.&nbsp;Avoid&nbsp;the&nbsp;concomitant&nbsp;use&nbsp;of strong UGT inducers (e.g., rifampicin, phenytoin, phenobarbital, ritonavir). If you must administer&nbsp;FERASIRO&nbsp;tablets&nbsp;with&nbsp;a&nbsp;strongUGT&nbsp;inducer, consider&nbsp;increasing&nbsp;the&nbsp;initial&nbsp;dose by&nbsp;50%,&nbsp;and&nbsp;monitor&nbsp;serum&nbsp;ferritin&nbsp;levels&nbsp;and&nbsp;clinical&nbsp;responsesfor&nbsp;further&nbsp;dose&nbsp;modification (see section 4.2 and section 4.5).</p><p><em>Bile&nbsp;Acid&nbsp;Sequestrants</em></p><p>Concomitant&nbsp;use&nbsp;of&nbsp;bile&nbsp;acid&nbsp;sequestrants&nbsp;decreases&nbsp;systemic&nbsp;exposure.&nbsp;Avoid&nbsp;the&nbsp;concomitant use of bile acid sequestrants (e.g., cholestyramine, colesevelam, colestipol). If you must administer&nbsp;FERASIRO&nbsp;tablets&nbsp;with&nbsp;a&nbsp;bileacid&nbsp;sequestrant,&nbsp;consider&nbsp;increasing&nbsp;the&nbsp;initial&nbsp;dose by&nbsp;50%,&nbsp;and&nbsp;monitor&nbsp;serum&nbsp;ferritin&nbsp;levels&nbsp;and&nbsp;clinicalresponses&nbsp;for&nbsp;further&nbsp;dose&nbsp;modification (see section 4.2 and section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FERASIRO is contraindicated in patients with:
•	Estimated GFR less than 40 mL/min/1.73 m2 (see section 4.2 and section 4.4)
•	Poor performance status (see section 4.4)
•	High-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy)
•	Advanced malignancies (see section 4.4)
•	Platelet counts less than 50 x 10 /L (see section 4.4)
•	Known hypersensitivity to deferasirox or any component of FERASIRO (see section 4.4 and section 4.8)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute Kidney Injury, Including Acute Renal Failure Requiring Dialysis and Renal Tubular Toxicity Including Fanconi Syndrome</strong></p><p>FERASIRO is contraindicated in patients with eGFR less than 40 mL/min/1.73 m<sup>2</sup>. Exercise caution&nbsp;in&nbsp;pediatricpatients&nbsp;with&nbsp;eGFR&nbsp;between&nbsp;40&nbsp;and&nbsp;60&nbsp;mL/minute/1.73&nbsp;m<sup>2</sup>.&nbsp;If&nbsp;treatment&nbsp;is needed, use the minimum effective dose and monitor renal function frequently. Individualize dose&nbsp;titration&nbsp;based&nbsp;on&nbsp;improvement&nbsp;in&nbsp;renal&nbsp;injury.&nbsp;For&nbsp;patientswith&nbsp;renal&nbsp;impairment&nbsp;(eGFR 40-60 mL/min/1.73 m<sup>2</sup>) reduce the starting dose by 50% (see section 4.2).</p><p>FERASIRO can cause acute kidney injury including renal failure requiring dialysis that has resulted in fatal outcomes. Based on postmarketing experience, most fatalities have occurred in&nbsp;patients&nbsp;with&nbsp;multiple&nbsp;comorbiditiesand&nbsp;who&nbsp;were&nbsp;in&nbsp;advanced&nbsp;stages&nbsp;of&nbsp;their&nbsp;hematological disorders. In the clinical trials, adults and pediatric deferasirox-treated patients with no preexisting renal disease experienced dose-dependent mild, non-progressive increases in serum creatinine and proteinuria.</p><p>Pre-existing renal disease and concomitant use of other nephrotoxic drugs may increase the risk of acute kidney injury in adult and pediatric patients. Acute illnesses associated with volume depletion and overchelation may increase the risk of acute kidney injury in pediatric patients. In pediatric patients, small decreases in eGFR can result in increases in deferasirox (tablets for&nbsp;oral suspension) exposure,&nbsp;particularly&nbsp;in younger&nbsp;patients with bodysurface area typical of patients less than age 7 years. This can lead to a cycle of worsening renal function andfurther increases&nbsp;in&nbsp;deferasirox&nbsp;exposure, unless&nbsp;the&nbsp;dose&nbsp;is&nbsp;reduced&nbsp;or interrupted. Renal tubular toxicity, including acquired Fanconi syndrome, has been reported in patients treated with&nbsp;deferasirox,&nbsp;most&nbsp;commonly&nbsp;in&nbsp;pediatricpatients&nbsp;with&nbsp;beta-thalassemia&nbsp;and&nbsp;serum&nbsp;ferritin levels less than 1,500 mcg/L. (see section 4.4, section 4.8 and section 5).</p><p>Evaluate&nbsp;renal&nbsp;glomerular&nbsp;and&nbsp;tubular&nbsp;function&nbsp;before&nbsp;initiating&nbsp;therapy&nbsp;or&nbsp;increasing&nbsp;the&nbsp;dose. Use prediction equations validated for use in adult and pediatric patients to estimate GFR. Obtain serum electrolytes and urinalysis in all patients to evaluate renal tubular function (see setion 4.2)</p><p>Monitor&nbsp;all&nbsp;patients&nbsp;for&nbsp;changes&nbsp;in&nbsp;eGFR&nbsp;and&nbsp;for&nbsp;renal&nbsp;tubular&nbsp;toxicity&nbsp;weekly&nbsp;during&nbsp;the&nbsp;first month&nbsp;after&nbsp;initiationor&nbsp;modification&nbsp;of&nbsp;therapy&nbsp;and&nbsp;at&nbsp;least&nbsp;monthly&nbsp;thereafter.&nbsp;Monitor&nbsp;serum&nbsp;ferritin&nbsp;monthly&nbsp;to&nbsp;evaluate&nbsp;for&nbsp;over&nbsp;chelation.&nbsp;Use&nbsp;the&nbsp;minimum&nbsp;dose&nbsp;to&nbsp;establish&nbsp;and&nbsp;maintain a low iron burden.</p><p>Monitor renal&nbsp;function&nbsp;more&nbsp;frequently&nbsp;in&nbsp;patients&nbsp;with&nbsp;preexisting&nbsp;renal&nbsp;disease&nbsp;or decreased renal function. In pediatric patients, interrupt FERASIRO during acute illnesses, which can cause volume depletion such as vomiting, diarrhea, or prolonged decreased oral intake, and monitor&nbsp;renal&nbsp;function&nbsp;more&nbsp;frequently.&nbsp;Promptly&nbsp;correct&nbsp;fluiddeficits&nbsp;to&nbsp;prevent&nbsp;renal&nbsp;injury. Resume therapy as appropriate, based on assessments of renal&nbsp;function, when oral intake and volume status are normal (see section 4.4, section 4.8 and section 5).</p><p>Hepatic&nbsp;Toxicity&nbsp;and&nbsp;Failure</p><p>FERASIRO can cause hepatic injury, fatal in some patients. In Study 1, 4 patients (1.3%) discontinued deferasirox because of hepatic toxicity (drug-induced hepatitis in 2 patients and increased serum transaminases in 2 additional patients). Hepatic toxicity appears to be more common&nbsp;in&nbsp;patients&nbsp;greater&nbsp;than&nbsp;55&nbsp;years&nbsp;of&nbsp;age.&nbsp;Hepatic&nbsp;failure&nbsp;wasmore&nbsp;common&nbsp;in&nbsp;patients with significant comorbidities, including liver cirrhosis and multiorgan failure (see section&nbsp;4.8).</p><p>Acute&nbsp;liver&nbsp;injury&nbsp;and&nbsp;failure,&nbsp;including&nbsp;fatal&nbsp;outcomes,&nbsp;have&nbsp;occurred&nbsp;in&nbsp;pediatric&nbsp;deferasirox- treated patients. Liver failure occurred in association with acute kidney injury in pediatric patients at risk for over chelation during a volume-depleting event. Interrupt FERASIRO therapy when acute liver injury or acute kidney injury is suspected and during volume depletion. Monitor liver and renal function more frequently in pediatric patients who are receiving FERASIRO in the 14-28 mg/kg/day range and when iron burden is approaching normal.&nbsp;Use&nbsp;theminimum&nbsp;effective&nbsp;dose&nbsp;to&nbsp;achieve&nbsp;and&nbsp;maintain&nbsp;a&nbsp;low&nbsp;iron&nbsp;burden&nbsp;(see&nbsp;section 4.2, section 4.4 and section 4.8).</p><p>Measure transaminases (AST and ALT) and bilirubin in all patients before the initiation of treatment and every 2 weeks during the first month and at least monthly thereafter. Consider dose modifications or interruption of treatment for severe or persistent elevations.</p><p>Avoid the use of FERASIRO in patients with severe (Child-Pugh C) hepatic impairment. Reduce the starting dose in patients with moderate (Child-Pugh B) hepatic impairment (see section 4.2). Patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment may be at higher risk for hepatic toxicity.</p><p><strong>Gastrointestinal&nbsp;(GI)&nbsp;Ulceration,&nbsp;Hemorrhage,&nbsp;and&nbsp;Perforation</strong></p><p>GI hemorrhage, including deaths, has been reported, especially in elderly patients who had advanced hematologic malignancies and/or low platelet counts. Nonfatal upper GI irritation, ulceration&nbsp;and&nbsp;hemorrhage&nbsp;have&nbsp;beenreported&nbsp;in&nbsp;patients, including&nbsp;children&nbsp;and&nbsp;adolescents, receiving deferasirox (see section 4.8). Monitor for signs and symptoms of GI ulceration and hemorrhage during FERASIRO therapy, and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. The risk of gastrointestinal hemorrhage may be increased when administering FERASIRO in combination with drugs that have ulcerogenic&nbsp;or&nbsp;hemorrhagicpotential,&nbsp;such&nbsp;as&nbsp;nonsteroidal&nbsp;anti-inflammatory&nbsp;drugs&nbsp;(NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. There have been reports of ulcers complicated with gastrointestinal perforation (including fatal outcome) (see section 4.8).</p><p><strong>Bone&nbsp;Marrow&nbsp;Suppression</strong></p><p>Neutropenia, agranulocytosis, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox. Preexisting hematologic disorders&nbsp;may&nbsp;increase&nbsp;this&nbsp;risk. Monitor&nbsp;blood&nbsp;countsin&nbsp;all&nbsp;patients.&nbsp;Interrupt treatment&nbsp;with deferasirox in patients who develop cytopenias until the cause of the cytopenia has been determined. FERASIRO is contraindicated in patients with platelet counts below 50 x 10 /L.</p><p>Age-Related&nbsp;Risk&nbsp;of&nbsp;Toxicity</p><p><em>Elderly&nbsp;Patients</em></p><p>Deferasirox (film-coated tablets) has been associated with serious and fatal adverse reactions in the postmarketingsetting among&nbsp;adults, predominantly in elderly patients.&nbsp;Monitor&nbsp;elderly patients treated with Deferasirox (film-coated tablets) more frequently for toxicity.</p><p><em>Pediatric&nbsp;Patients</em></p><p>Deferasirox (film-coated tablets) has been associated with serious and fatal adverse reactions in&nbsp;pediatric&nbsp;patients&nbsp;inthe&nbsp;postmarketing&nbsp;setting.&nbsp;These&nbsp;events&nbsp;were&nbsp;frequently&nbsp;associated&nbsp;with volume depletion or with continued deferasirox (tablets for oral suspension) doses in the 20- 40 mg/kg/day range equivalent to 14-28 mg/kg/day deferasirox (film-coated tablets) when body iron burden was approaching or in the normal range. Interrupt deferasirox (film-coated tablets) in patients with volume depletion, and&nbsp;resume deferasirox (film-coated tablets) when renal&nbsp;function&nbsp;and&nbsp;fluid&nbsp;volume&nbsp;have&nbsp;normalized.&nbsp;Monitor&nbsp;liver&nbsp;and&nbsp;renal&nbsp;function&nbsp;more&nbsp;frequently during&nbsp;volume&nbsp;depletion&nbsp;and in&nbsp;patients&nbsp;receiving&nbsp;deferasirox&nbsp;(film-coated tablets) in the 14-28 mg/kg/day range when iron burden is approaching the normal range. Use the minimum&nbsp;effective&nbsp;dose&nbsp;to&nbsp;achieveand&nbsp;maintain&nbsp;a&nbsp;low&nbsp;iron&nbsp;burden&nbsp;(see&nbsp;section&nbsp;4.2&nbsp;and&nbsp;section&nbsp;4.4).</p><p><strong>Overchelation</strong></p><p>For patients with transfusional iron overload, measure serum ferritin monthly to assess for possible over chelation of iron. An analysis of pediatric patients treated with deferasirox (tablets for oral suspension)&nbsp;in pooled clinical trials (n =158), found a higher rate of renal adverse&nbsp;events&nbsp;(AEs)&nbsp;among&nbsp;patients&nbsp;receiving doses&nbsp;greater&nbsp;than&nbsp;25 mg/kg/day equivalent&nbsp;to</p><p>17.5 mg/kg/day deferasirox (film-coated tablets) while their serum ferritin values were less than&nbsp;1000&nbsp;mcg/L. Consider&nbsp;dose&nbsp;reduction&nbsp;or&nbsp;closer&nbsp;monitoring&nbsp;of&nbsp;renal&nbsp;and&nbsp;hepatic&nbsp;function, and serum ferritin levels during these periods. Use the minimum effective dose to maintain a low-iron burden. (see section 4.8)</p><p>If the serum ferritin falls below 1000 mcg/L at 2 consecutive visits, consider dose reduction, especially&nbsp;if&nbsp;thedeferasirox&nbsp;(film-coated&nbsp;tablets)&nbsp;dose&nbsp;is&nbsp;greater&nbsp;than&nbsp;17.5&nbsp;mg/kg/day&nbsp;(see section 4.8). If the serum ferritin falls below 500 mcg/L, interrupt therapy with&nbsp;deferasirox&nbsp;(film-coated tablets) and continue monthly monitoring.</p><p>Evaluate the need for ongoing chelation for patients whose conditions do not require regular blood&nbsp;transfusions.Use&nbsp;the&nbsp;minimum&nbsp;effective&nbsp;dose&nbsp;to&nbsp;maintain&nbsp;iron&nbsp;burden&nbsp;in&nbsp;the&nbsp;target&nbsp;range. Continued&nbsp;administration&nbsp;of&nbsp;deferasirox(film-coated&nbsp;tablets)&nbsp;in&nbsp;the&nbsp;14&nbsp;to&nbsp;28&nbsp;mg/kg/day&nbsp;range, when the body iron burden is approaching or within the normal range can result in life threatening adverse events (see section 4.2)</p><p>For patients&nbsp;with&nbsp;NTDT, measure&nbsp;serum&nbsp;ferritin&nbsp;monthly, and&nbsp;if&nbsp;the&nbsp;serum&nbsp;ferritin&nbsp;falls&nbsp;below 300 mcg/L, interrupt deferasirox (film-coated tablets) and obtain a confirmatory LIC e.g&nbsp;Biopsy.</p><p><strong>Hypersensitivity</strong></p><p>Deferasirox (film-coated tablets) may cause serious hypersensitivity reactions (such as anaphylaxis&nbsp;and angioedema), with theonset of the&nbsp;reaction usually occurring within the&nbsp;first month of treatment (see section 4.8). If reactions are severe, discontinue Deferasirox (film- coated&nbsp;tablets)&nbsp;and&nbsp;institute&nbsp;appropriate&nbsp;medical&nbsp;intervention.&nbsp;Deferasirox&nbsp;(film-coated&nbsp;tablets) is&nbsp;contraindicatedin&nbsp;patients&nbsp;with&nbsp;known&nbsp;hypersensitivity&nbsp;to&nbsp;deferasirox&nbsp;products&nbsp;and&nbsp;should&nbsp;not be reintroduced in patients who have experienced previous hypersensitivity reactions on deferasirox products due to the risk of anaphylactic shock.</p><p><strong>Severe&nbsp;Skin&nbsp;Reactions</strong></p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic&nbsp;epidermalnecrolysis&nbsp;(TEN)&nbsp;and&nbsp;drug&nbsp;reaction&nbsp;with&nbsp;eosinophilia&nbsp;and&nbsp;systemic&nbsp;symptoms (DRESS) which could be life-threatening or fatal have been reported during deferasirox therapy (see section 4.8). Cases of erythema multiforme have been observed. Advise patients of the signs and symptoms of severe skin reactions, and closely monitor. If any severe skin reactions&nbsp;are&nbsp;suspected, discontinue Deferasirox&nbsp;(film-coated&nbsp;tablets) immediately and&nbsp;do&nbsp;not reintroduce deferasirox therapy.</p><p><strong>Skin&nbsp;Rash</strong></p><p>Rashes may occur during deferasirox (film-coated tablets) treatment (see section 4.8). For rashes&nbsp;of&nbsp;mild-tomoderate&nbsp;severity,&nbsp;deferasirox&nbsp;(film-coated&nbsp;tablets)&nbsp;may&nbsp;be&nbsp;continued&nbsp;without dose adjustment, since the rash often resolves spontaneously. In severe cases, interrupt treatment with&nbsp;deferasirox. Reintroduction&nbsp;at a&nbsp;lower dose with&nbsp;escalation may&nbsp;be&nbsp;considered after resolution of the rash.</p><p><strong>Auditory&nbsp;and&nbsp;Ocular&nbsp;Abnormalities</strong></p><p>Auditory disturbances (high frequency hearing loss, decreased hearing), and ocular disturbances&nbsp;(lens&nbsp;opacities,cataracts,&nbsp;elevations&nbsp;in&nbsp;intraocular&nbsp;pressure,&nbsp;and&nbsp;retinal&nbsp;disorders) were reported at a frequency of less than 1% with deferasirox therapy in the clinical studies. The frequency of auditory adverse events irrespective of causality was increased among&nbsp;pediatric&nbsp;patients,&nbsp;who&nbsp;received&nbsp;deferasirox&nbsp;(tablets&nbsp;for&nbsp;oral&nbsp;suspension) doses&nbsp;greater&nbsp;than&nbsp;25 mg/kg/day&nbsp;equivalent&nbsp;to&nbsp;17.5&nbsp;mg/kg/day&nbsp;deferasirox&nbsp;(film-coated&nbsp;tablets) when&nbsp;serum&nbsp;ferritin was less than 1000 mcg/L. (see section 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of deferasirox in combination with other iron chelators has not been established. Therefore, it must not be combined with other iron chelator therapies (see section 4.3).</p><p><u>Interaction&nbsp;with&nbsp;food</u></p><p>The Cmax&nbsp;of deferasirox film-coated tablets was increased (by 29%) when taken with a high-&nbsp;fat meal. Deferasirox film-coated tablets may be taken either on an empty stomach or with a light meal, preferably at the same time each day (see sections 4.2 and 5.2).</p><p><u>Agents&nbsp;that&nbsp;may&nbsp;decrease&nbsp;Deferasirox systemic&nbsp;exposure</u></p><p>Deferasirox metabolism depends on UGT enzymes. In a healthy volunteer study, the concomitant administration of deferasirox (single dose of 30 mg/kg,) and the potent UGT inducer, rifampicin, (repeated dose of 600 mg/day) resulted in a decrease of deferasirox exposure&nbsp;by&nbsp;44%&nbsp;(90%&nbsp;CI:&nbsp;37%&nbsp;-&nbsp;51%).&nbsp;Therefore,&nbsp;the&nbsp;concomitant&nbsp;use&nbsp;ofDeferasirox&nbsp;tablets with potent UGT inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, ritonavir) may&nbsp;result in&nbsp;a decrease in Deferasirox efficacy. The&nbsp;patient&#39;s serum&nbsp;ferritin&nbsp;should be monitored during and after the combination, and the dose of Deferasirox adjusted if&nbsp;necessary.</p><p>Cholestyramine significantly reduced the deferasirox exposure in a mechanistic study to determine the degree of enterohepatic recycling (see section 5.2).</p><p><u>Interaction&nbsp;with&nbsp;midazolam&nbsp;and&nbsp;other agents&nbsp;metabolised&nbsp;by&nbsp;CYP3A4</u></p><p>In a&nbsp;healthy&nbsp;volunteer&nbsp;study, the&nbsp;concomitant administration of&nbsp;deferasirox and&nbsp;midazolam&nbsp;(a CYP3A4&nbsp;probesubstrate)&nbsp;resulted&nbsp;in&nbsp;a&nbsp;decrease&nbsp;of&nbsp;midazolam&nbsp;exposure&nbsp;by&nbsp;17%&nbsp;(90%&nbsp;CI:&nbsp;8%</p><p>-&nbsp;26%).&nbsp;In&nbsp;the&nbsp;clinical&nbsp;setting,&nbsp;this&nbsp;effect&nbsp;may&nbsp;be&nbsp;more&nbsp;pronounced.&nbsp;Therefore,&nbsp;due&nbsp;to&nbsp;a&nbsp;possible decrease in efficacy, caution should be exercised when deferasirox is combined with substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil, ergotamine).</p><p><u>Interaction&nbsp;with&nbsp;repaglinide&nbsp;and&nbsp;other agents&nbsp;metabolised by&nbsp;CYP2C8</u></p><p>In a healthy volunteer study, the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor (30 mg/kg daily), with repaglinide, a CYP2C8 substrate, given as a single&nbsp;dose&nbsp;of&nbsp;0.5&nbsp;mg, increased repaglinide&nbsp;AUCand&nbsp;Cmax&nbsp;about&nbsp;2.3-fold&nbsp;(90%&nbsp;CI&nbsp;[2.03-2.63])&nbsp;and&nbsp;1.6-fold&nbsp;(90%&nbsp;CI&nbsp;[1.42-1.84]),&nbsp;respectively.&nbsp;Since&nbsp;the&nbsp;interactionhas&nbsp;not&nbsp;been&nbsp;established&nbsp;with dosages&nbsp;higher&nbsp;than&nbsp;0.5&nbsp;mg&nbsp;for&nbsp;repaglinide,&nbsp;the&nbsp;concomitant&nbsp;use&nbsp;of&nbsp;deferasirox&nbsp;withrepaglinide should&nbsp;be&nbsp;avoided.&nbsp;If&nbsp;the&nbsp;combination&nbsp;appears&nbsp;necessary,&nbsp;careful&nbsp;clinical&nbsp;and&nbsp;blood&nbsp;glucose&nbsp;monitoring should be performed (see section 4.4). An interaction between deferasirox and other CYP2C8 substrates like paclitaxel cannot be excluded.</p><p><u>Interaction&nbsp;with&nbsp;theophylline&nbsp;and&nbsp;other&nbsp;agents&nbsp;metabolised by&nbsp;CYP1A2</u></p><p>In a healthy volunteer study, the concomitant administration of deferasirox as a CYP1A2 inhibitor&nbsp;(repeated&nbsp;dose&nbsp;of30&nbsp;mg/kg/day)&nbsp;and&nbsp;the&nbsp;CYP1A2&nbsp;substrate&nbsp;theophylline&nbsp;(single&nbsp;dose of 120 mg) resulted in an increase of theophylline&nbsp;AUC by 84% (90% CI: 73% to&nbsp;95%). The&nbsp;single dose Cmax&nbsp;was not affected, but an increase of</p><p>theophylline&nbsp;Cmax&nbsp;is&nbsp;expected&nbsp;to&nbsp;occur&nbsp;with&nbsp;chronic&nbsp;dosing. Therefore,&nbsp;the&nbsp;concomitant&nbsp;use&nbsp;of&nbsp;deferasirox with theophylline is not recommended. If deferasirox and theophylline are used concomitantly, monitoring of theophylline concentration and theophylline dose reduction should&nbsp;be&nbsp;considered.&nbsp;An&nbsp;interaction&nbsp;betweendeferasirox&nbsp;and&nbsp;other&nbsp;CYP1A2&nbsp;substrates&nbsp;cannot be excluded. For substances that are predominantly metabolised by CYP1A2 and that have a narrow therapeutic index&nbsp;(e.g. clozapine, tizanidine), the same recommendations apply as for&nbsp;theophylline.</p><p><u>Other&nbsp;information</u></p><p>The&nbsp;concomitant&nbsp;administration&nbsp;of&nbsp;deferasirox&nbsp;and&nbsp;aluminium-containing&nbsp;antacid&nbsp;preparations has not been formally studied. Although deferasirox has a lower affinity for aluminium than for iron, it&nbsp;is not&nbsp;recommended&nbsp;to takedeferasirox tablets with&nbsp;aluminium-containing antacid&nbsp;preparations.</p><p>The concomitant administration of deferasirox with substances that have known ulcerogenic potential, such as NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral bisphosphonates may increase the risk of gastrointestinal toxicity (see section 4.4). The concomitant administration of deferasirox with anticoagulants may also increase the risk of gastrointestinal haemorrhage. Close clinical monitoring is required when deferasirox is combined with these substances.</p><p>Concomitant administration of deferasirox and busulfan resulted in an increase of busulfan exposure&nbsp;(AUC),&nbsp;butthe&nbsp;mechanism&nbsp;of&nbsp;the&nbsp;interaction&nbsp;remains&nbsp;unclear.&nbsp;If&nbsp;possible,&nbsp;evaluation of&nbsp;the&nbsp;pharmacokinetics&nbsp;(AUC,&nbsp;clearance)of&nbsp;a&nbsp;busulfan&nbsp;test&nbsp;dose&nbsp;should&nbsp;be&nbsp;performed&nbsp;to&nbsp;allow dose adjustment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No clinical data on exposed pregnancies are available for deferasirox. Studies in animals have shown some reproductive toxicity at maternally toxic doses (see section 5.3). The potential risk for humans is unknown.</p><p>As a precaution, it is recommended that FERASIRO is not used during pregnancy unless clearly necessary.</p><p>Deferasirox&nbsp;may&nbsp;decrease&nbsp;the&nbsp;efficacy&nbsp;of&nbsp;hormonal&nbsp;contraceptives&nbsp;(see&nbsp;section&nbsp;4.5).&nbsp;Women of childbearing potential are recommended to use additional or alternative non-hormonal&nbsp;methods of contraception when using Deferasirox.</p><p><u>Breast-feeding</u></p><p>In&nbsp;animal&nbsp;studies,&nbsp;deferasirox&nbsp;was&nbsp;found&nbsp;to&nbsp;be&nbsp;rapidly&nbsp;and&nbsp;extensively&nbsp;secreted&nbsp;into&nbsp;maternal milk. No effect on the offspring was noted. It is not known if deferasirox is secreted into human milk. Breast-feeding while taking FERASIRO is not recommended.</p><p><u>Fertility</u></p><p>No fertility data is available for humans. In animals, no adverse effects on male or female fertility were found (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Deferasirox has minor influence on the ability to drive and use machines. Patients experiencing the uncommon adverse reaction of dizziness should exercise caution when driving or operating machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of&nbsp;the safety&nbsp;profile</u></p><p>The most frequent reactions reported&nbsp;during&nbsp;chronic treatment in&nbsp;clinical studies conducted with&nbsp;deferasirox&nbsp;inadult&nbsp;and&nbsp;paediatric&nbsp;patients&nbsp;include&nbsp;gastrointestinal&nbsp;disturbances&nbsp;(mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash. Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years and in the elderly. These reactions are dose-dependent, mostly mild to moderate, generally transient and mostly resolve even if treatment is continued.</p><p>During&nbsp;clinical&nbsp;studies&nbsp;dose-dependent&nbsp;increases&nbsp;in&nbsp;serum&nbsp;creatinine&nbsp;occurred&nbsp;in&nbsp;about&nbsp;36% of patients, though most remained within the normal range. Decreases in mean creatinine clearance&nbsp;have&nbsp;been&nbsp;observed&nbsp;in&nbsp;bothpaediatric&nbsp;and&nbsp;adult&nbsp;patients&nbsp;with&nbsp;beta-thalassemia&nbsp;and iron overload during the first year of treatment, but there is evidence that this does not decrease further in subsequent years of treatment. Elevations of liver transaminases have been&nbsp;reported.&nbsp;Safety&nbsp;monitoring&nbsp;schedules&nbsp;for&nbsp;renal&nbsp;and&nbsp;liver&nbsp;parameters&nbsp;are&nbsp;recommended. Auditory (decreased hearing) and ocular (lens opacities) disturbances are uncommon, and yearly examinations are also recommended (see section 4.4).</p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of Deferasirox (see section 4.4).</p><p><u>Tabulated&nbsp;list of&nbsp;adverse&nbsp;reactions</u></p><p>Adverse reactions are&nbsp;ranked&nbsp;below using&nbsp;the&nbsp;following convention:&nbsp;very&nbsp;common&nbsp;(&ge;1/10); common&nbsp;(&ge;1/100&nbsp;to&lt;1/10); uncommon&nbsp;(&ge;1/1,000&nbsp;to&nbsp;&lt;1/100);&nbsp;rare&nbsp;(&ge;1/10,000&nbsp;to&nbsp;&lt;1/1,000); very&nbsp;rare&nbsp;(&lt;1/10,000);&nbsp;not&nbsp;known&nbsp;(cannotbe&nbsp;estimated&nbsp;from&nbsp;the&nbsp;available&nbsp;data).&nbsp;Within&nbsp;each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><u>Table&nbsp;5</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Pancytopenia<sup>1</sup>,&nbsp;thrombocytopenia<sup>1</sup>,&nbsp;anaemia&nbsp;aggravated<sup>1</sup>,&nbsp;neutropenia<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune&nbsp;system&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Hypersensitivity&nbsp;&nbsp;reactions&nbsp;&nbsp;(including&nbsp;&nbsp;anaphylactic&nbsp;&nbsp;reactions&nbsp;&nbsp;and</p><p>angioedema)<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Metabolic&nbsp;acidosis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anxiety,&nbsp;sleep&nbsp;disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous&nbsp;system&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cataract,&nbsp;maculopathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Optic&nbsp;neuritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear&nbsp;and&nbsp;labyrinth&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal&nbsp;disorders</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Laryngeal&nbsp;pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea,&nbsp;constipation,&nbsp;vomiting,&nbsp;nausea,&nbsp;abdominal&nbsp;pain,&nbsp;abdominal</p><p>distension,&nbsp;dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrointestinal&nbsp;haemorrhage,&nbsp;gastric&nbsp;ulcer&nbsp;(including&nbsp;multiple&nbsp;ulcers),</p><p>duodenal&nbsp;ulcer,&nbsp;gastritis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Oesophagitis</p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Gastrointestinal&nbsp;perforation<sup>1</sup>,&nbsp;acute&nbsp;pancreatitis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Transaminases&nbsp;increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatitis,&nbsp;cholelithiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Hepatic&nbsp;failure<sup>1,</sup>&nbsp;<sup>2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash,&nbsp;pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pigmentation&nbsp;disorder</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Drug&nbsp;reaction&nbsp;with&nbsp;eosinophilia&nbsp;and&nbsp;systemic&nbsp;symptoms&nbsp;(DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Stevens-Johnson&nbsp;syndrome<sup>1</sup>,&nbsp;hypersensitivity&nbsp;vasculitis<sup>1</sup>,&nbsp;urticaria<sup>1</sup>,</p><p>erythema&nbsp;multiforme<sup>1</sup>,&nbsp;alopecia<sup>1</sup>,&nbsp;toxic&nbsp;epidermal&nbsp;necrolysis&nbsp;(TEN)<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ver&nbsp;common</p></td><td style="vertical-align:top"><p>Blood&nbsp;creatinine&nbsp;increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Proteinuria</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Renal&nbsp;tubular&nbsp;disorder<sup>2</sup>&nbsp;(acquired&nbsp;Fanconi&nbsp;syndrome),&nbsp;glycosuria</p></td></tr><tr><td style="vertical-align:top"><p>Not&nbsp;known</p></td><td style="vertical-align:top"><p>Acute&nbsp;renal&nbsp;failure<sup>1,</sup>&nbsp;<sup>2</sup>,&nbsp;tubulointerstitial&nbsp;nephritis<sup>1</sup>,&nbsp;nephrolithiasis<sup>1</sup>,renal</p><p>tubular&nbsp;necrosis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pyrexia,&nbsp;oedema,&nbsp;fatigue</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Adverse reactions reported during post-marketing experience. These are derived from spontaneous reports for which it is not always possible to reliably establish frequency or a causal relationship to exposure to the medicinal product.</p><p><sup>2</sup>&nbsp;Severe&nbsp;forms&nbsp;associated&nbsp;with&nbsp;changes&nbsp;in&nbsp;consciousness&nbsp;in&nbsp;the&nbsp;context&nbsp;of&nbsp;hyperammonaemic encephalopathy have been reported.</p><p><u>Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions</u></p><p>Gallstones&nbsp;and&nbsp;related&nbsp;biliary&nbsp;disorders&nbsp;were&nbsp;reported&nbsp;in&nbsp;about&nbsp;2%&nbsp;of&nbsp;patients.&nbsp;Elevations&nbsp;of liver transaminases were reported as an adverse reaction in 2% of patients. Elevations of transaminases greater than 10 times the upper limit of the normal range, suggestive of hepatitis, were uncommon (0.3%). During post-marketing experience, hepatic failure, sometimes fatal, has been reported with the deferasirox, especially in patients with preexisting&nbsp;liver&nbsp;cirrhosis&nbsp;(see&nbsp;section&nbsp;4.4).&nbsp;There&nbsp;have&nbsp;been&nbsp;post-marketing&nbsp;reports&nbsp;of&nbsp;metabolic acidosis. The majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid-base imbalance is a known complication (see section 4.4). Cases of serious acute pancreatitis were observed without documented underlying biliary conditions. As with other iron chelator treatment, high- frequency hearing loss and lenticular opacities (early cataracts) have been uncommonly observed in patients treated with deferasirox (see section 4.4).</p><p><u>Creatinine&nbsp;clearance&nbsp;in transfusional iron&nbsp;overload</u></p><p>In&nbsp;a&nbsp;retrospective&nbsp;meta-analysis&nbsp;of&nbsp;2,102&nbsp;adult&nbsp;and&nbsp;paediatric&nbsp;beta-thalassaemia&nbsp;patients&nbsp;with transfusional iron overload treated with deferasirox in two randomised and four open label studies of up&nbsp;to&nbsp;five&nbsp;years&#39; duration, a mean&nbsp;creatinine clearance decrease of 13.2% in&nbsp;adult patients&nbsp;(95%&nbsp;CI:&nbsp;-14.4%&nbsp;to&nbsp;-12.1%;&nbsp;n=935)&nbsp;and&nbsp;9.9%(95%&nbsp;CI:&nbsp;-11.1%&nbsp;to&nbsp;-8.6%;&nbsp;n=1,142)</p><p>in paediatric patients was observed during the first year of treatment. In 250 patients who were followed for up to five years, no further decrease in mean creatinine clearance levels was observed.</p><p><u>Clinical&nbsp;study&nbsp;in&nbsp;patients&nbsp;with&nbsp;non-transfusion-dependent&nbsp;thalassaemia&nbsp;syndromes</u></p><p>In a 1-year study in patients with non-transfusion-dependent thalassaemia syndromes and iron&nbsp;overload&nbsp;(at&nbsp;a&nbsp;doseof&nbsp;10&nbsp;mg/kg/day),&nbsp;diarrhoea&nbsp;(9.1%),&nbsp;rash&nbsp;(9.1%),&nbsp;and&nbsp;nausea&nbsp;(7.3%) were the most frequent study drug-related adverse events. Abnormal serum creatinine and creatinine clearance values were reported in 5.5% and 1.8% of patients, respectively. Elevations&nbsp;of&nbsp;liver&nbsp;transaminases&nbsp;greater&nbsp;than&nbsp;2&nbsp;times&nbsp;the&nbsp;baseline&nbsp;and&nbsp;5&nbsp;times&nbsp;the&nbsp;upper&nbsp;limit of normal were reported in 1.8% of patients.</p><p><em><u>Paediatric&nbsp;population</u></em></p><p>In two clinical studies, growth and sexual development of paediatric patients treated with deferasirox for up to 5 years were not affected (see section 4.4).</p><p>Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years than in older&nbsp;patients.</p><p>Renal tubulopathy has been mainly reported in children and adolescents with beta- thalassaemia treated with deferasirox. In post-marketing reports, a high proportion of cases of metabolic acidosis occurred in children in the context of Fanconi syndrome.</p><p>Acute&nbsp;pancreatitis&nbsp;has&nbsp;been reported,&nbsp;particularly&nbsp;in&nbsp;children and&nbsp;adolescents.</p><p>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals&nbsp;are asked toreport any&nbsp;suspected adverse reactions&nbsp;to&nbsp;the competent authority in Saudi Arabia as per details below:</p><p>To&nbsp;report&nbsp;any&nbsp;side&nbsp;effect(s):</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]--><strong><u>Saudi&nbsp;Arabia</u></strong></p><p>The&nbsp;National Pharmacovigilance&nbsp;and Drug&nbsp;Safety&nbsp;Centre&nbsp;(NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax:&nbsp;+966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222, Ext&nbsp;2317-2356-2340</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->SFDA&nbsp;Call Center:&nbsp;19999</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;https://ade.sfda.gov.sa/</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]--><strong><u>Other&nbsp;GCC&nbsp;States:</u></strong></p><p>Please&nbsp;contact the&nbsp;relevant competent&nbsp;authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Early&nbsp;signs&nbsp;of&nbsp;acute&nbsp;overdose&nbsp;are&nbsp;digestive&nbsp;effects&nbsp;such&nbsp;as&nbsp;abdominal&nbsp;pain,&nbsp;diarrhoea,&nbsp;nausea&nbsp;and&nbsp;vomiting.&nbsp;Hepaticand&nbsp;renal&nbsp;disorders&nbsp;have&nbsp;been&nbsp;reported,&nbsp;including&nbsp;cases&nbsp;of&nbsp;liver enzyme&nbsp;and&nbsp;creatinine&nbsp;increased&nbsp;withrecovery&nbsp;after&nbsp;treatment&nbsp;discontinuation.&nbsp;An erroneously administered single dose of 90 mg/kg&nbsp;led to Fanconi syndrome which&nbsp;resolved after treatment.</p><p>There&nbsp;is&nbsp;no&nbsp;specific&nbsp;antidote&nbsp;for&nbsp;deferasirox.&nbsp;Standard&nbsp;procedures&nbsp;for&nbsp;management&nbsp;of overdose may be indicated as well as symptomatic treatment, as medically appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong><!--[endif]--><strong><em>Pharmacotherapeutic&nbsp;group:&nbsp;</em></strong>Iron&nbsp;chelating&nbsp;agents&nbsp;<br /><strong><em>ATC code</em></strong>: V03AC03</p><p><u>Mechanism&nbsp;of&nbsp;action</u></p><p>Deferasirox is&nbsp;an&nbsp;orally&nbsp;active&nbsp;chelator that&nbsp;is&nbsp;highly&nbsp;selective&nbsp;for iron&nbsp;(III). It&nbsp;is&nbsp;a&nbsp;tridentate ligand&nbsp;that&nbsp;binds&nbsp;ironwith&nbsp;high&nbsp;affinity&nbsp;in&nbsp;a&nbsp;2:1&nbsp;ratio.&nbsp;Deferasirox&nbsp;promotes&nbsp;excretion&nbsp;of&nbsp;iron,&nbsp;primarily&nbsp;in the&nbsp;faeces. Deferasirox&nbsp;has low affinity for&nbsp;zinc and&nbsp;copper and&nbsp;does not&nbsp;cause constant low serum levels of these metals.</p><p><u>Pharmacodynamic&nbsp;effects</u></p><p>In&nbsp;an&nbsp;iron-balance&nbsp;metabolic&nbsp;study&nbsp;in&nbsp;iron-overloaded&nbsp;adult&nbsp;thalassaemic&nbsp;patients, deferasirox&nbsp;at&nbsp;daily&nbsp;dosesof&nbsp;10,&nbsp;20&nbsp;and&nbsp;40&nbsp;mg/kg&nbsp;induced&nbsp;the&nbsp;mean&nbsp;net&nbsp;excretion&nbsp;of&nbsp;0.119,</p><p>0.329&nbsp;and&nbsp;0.445&nbsp;mg&nbsp;Fe/kg&nbsp;body&nbsp;weight/day,&nbsp;respectively.&nbsp;<u>Clinical efficacy and safety</u></p><p>Deferasirox has been investigated in 411 adult (age &ge;16 years) and 292 paediatric patients (aged&nbsp;2&nbsp;to&nbsp;&lt;16&nbsp;years)with&nbsp;chronic&nbsp;iron&nbsp;overload&nbsp;due&nbsp;to&nbsp;blood&nbsp;transfusions.&nbsp;Of&nbsp;the&nbsp;paediatric patients&nbsp;52&nbsp;were&nbsp;aged&nbsp;2&nbsp;to&nbsp;5&nbsp;years.&nbsp;Theunderlying&nbsp;conditions&nbsp;requiring&nbsp;transfusion&nbsp;included beta-thalassaemia, sickle cell disease and other congenital and acquired anaemias (myelodysplastic&nbsp;syndromes,&nbsp;Diamond-Blackfan&nbsp;syndrome,&nbsp;aplastic&nbsp;anaemia&nbsp;and&nbsp;othervery rare anaemias).</p><p>Daily&nbsp;treatment&nbsp;with&nbsp;the&nbsp;deferasirox&nbsp;formulation&nbsp;at&nbsp;doses&nbsp;of&nbsp;20&nbsp;and&nbsp;30&nbsp;mg/kg&nbsp;for&nbsp;one&nbsp;year&nbsp;in frequently transfused adult and paediatric patients with beta-thalassaemia led to reductions in indicators of total body iron; liver iron concentration was reduced by about -0.4 and -8.9 mg Fe/g liver (biopsy dry weight (dw)) on average, respectively, and serum ferritin was reduced by about -36 and&nbsp;-926&nbsp;&mu;g/l&nbsp;on average, respectively. At&nbsp;these same doses the&nbsp;ratios of&nbsp;iron&nbsp;excretion:&nbsp;iron&nbsp;intake&nbsp;were&nbsp;1.02&nbsp;(indicating&nbsp;net&nbsp;iron&nbsp;balance)&nbsp;and&nbsp;1.67&nbsp;(indicating&nbsp;net iron removal), respectively.</p><p>Deferasirox&nbsp;induced&nbsp;similar&nbsp;responses&nbsp;in&nbsp;iron-overloaded&nbsp;patients&nbsp;with&nbsp;other&nbsp;anaemias.&nbsp;Daily doses&nbsp;of&nbsp;10&nbsp;mg/kg&nbsp;forone&nbsp;year&nbsp;could&nbsp;maintain&nbsp;liver&nbsp;iron&nbsp;and&nbsp;serum&nbsp;ferritin&nbsp;levels&nbsp;and&nbsp;induce net iron balance in patients receiving infrequent transfusions or exchange transfusions. Serum&nbsp;ferritin&nbsp;assessed&nbsp;by&nbsp;monthly&nbsp;monitoring reflectedchanges&nbsp;in&nbsp;liver&nbsp;iron&nbsp;concentration indicating that trends in serum ferritin can be used to monitor response to therapy. Limited clinical data (29 patients with normal cardiac function at baseline) using MRI indicate that treatment with deferasirox 10-30&nbsp;mg/kg/day&nbsp;for 1&nbsp;year may&nbsp;also reduce&nbsp;levels of iron&nbsp;in&nbsp;the heart (on average, MRI T2* increased from 18.3 to 23.0 milliseconds).</p><p>The principal analysis of the pivotal comparative&nbsp;study in 586 patients suffering&nbsp;from beta- thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox&nbsp;to&nbsp;deferoxamine&nbsp;in the&nbsp;analysis&nbsp;ofthe&nbsp;total&nbsp;patient&nbsp;population.&nbsp;It&nbsp;appeared&nbsp;from&nbsp;a&nbsp;post-hoc&nbsp;analysis&nbsp;of&nbsp;this&nbsp;study&nbsp;that,&nbsp;in&nbsp;the&nbsp;subgroup&nbsp;of&nbsp;patients&nbsp;with&nbsp;liver&nbsp;iron&nbsp;concentration&nbsp;&ge;7 mg Fe/g dw treated with deferasirox (20 and 30 mg/kg) or deferoxamine (35 to &ge;50 mg/kg), the non-inferiority criteria were achieved. However, in patients with liver iron concentration&nbsp;&lt;7&nbsp;mg&nbsp;Fe/g&nbsp;dw&nbsp;treated&nbsp;withdeferasirox&nbsp;(5&nbsp;and&nbsp;10&nbsp;mg/kg)&nbsp;or&nbsp;deferoxamine&nbsp;(20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.&nbsp;This&nbsp;imbalance&nbsp;occurred&nbsp;because&nbsp;patients&nbsp;on&nbsp;deferoxamine&nbsp;wereallowed&nbsp;to&nbsp;remain on their pre-study dose even if it was higher than the protocol specified dose. Fifty-six patients under the age of 6 years participated in this pivotal study, 28 of them receiving&nbsp;deferasirox.</p><p>It appeared from preclinical and clinical studies that deferasirox could be as active as deferoxamine when used in a&nbsp;dose&nbsp;ratio of 2:1 (i.e.&nbsp;a&nbsp;dose&nbsp;of deferasirox that is&nbsp;numerically half of the deferoxamine dose). For deferasirox film-coated tablets, a dose ratio of 3:1 can be considered (i.e. a dose of deferasirox film-coated tablets that is numerically one third of the deferoxamine dose). However, this dosing recommendation was not prospectively assessed in the clinical studies.</p><p>In addition, in patients with liver iron concentration &ge;7 mg Fe/g dw with various rare anaemias or sickle cell disease, deferasirox up to 20 and 30 mg/kg produced a decrease in liver&nbsp;iron&nbsp;concentration&nbsp;and&nbsp;serum&nbsp;ferritincomparable&nbsp;to&nbsp;that&nbsp;obtained&nbsp;in&nbsp;patients&nbsp;with&nbsp;beta-&nbsp;thalassaemia.</p><p>In&nbsp;a&nbsp;5-year&nbsp;observational&nbsp;study&nbsp;in&nbsp;which&nbsp;267&nbsp;children&nbsp;aged&nbsp;2&nbsp;to&nbsp;&lt;6&nbsp;years&nbsp;(at&nbsp;enrollment)&nbsp;with transfusional haemosiderosis received deferasirox, there were no clinically meaningful differences in the safety and tolerability profile of Deferasirox in paediatric patients aged 2 to&nbsp;&lt;6&nbsp;years&nbsp;compared&nbsp;to&nbsp;the&nbsp;overall&nbsp;adult&nbsp;and&nbsp;older&nbsp;paediatricpopulation,&nbsp;including&nbsp;increases in serum creatinine of&nbsp;&gt;33% and above the upper limit of normal on &ge;2 consecutive occasions (3.1%), and elevation&nbsp;of&nbsp;alanine aminotransferase (ALT) greater&nbsp;than 5&nbsp;times the upper limit of normal (4.3%). Single events of increase in ALT and aspartate aminotransferase were reported in 20.0% and 8.3%, respectively, of the 145 patients who completed the study.</p><p>In a study to assess the safety of deferasirox film-coated and dispersible tablets, 173 adult and&nbsp;paediatricpatients&nbsp;with&nbsp;transfusion&nbsp;dependent&nbsp;thalassaemia&nbsp;or&nbsp;myelodysplastic&nbsp;syndrome were treated for 24 weeks. A comparable safety profile for film-coated and dispersible tablets was observed.</p><p>In patients with non-transfusion-dependent thalassaemia syndromes and iron overload, treatment&nbsp;with&nbsp;deferasirox dispersible&nbsp;tablets&nbsp;was&nbsp;assessed&nbsp;in&nbsp;a&nbsp;1-year, randomised, double- blind,&nbsp;placebo-controlled&nbsp;study.&nbsp;The&nbsp;studycompared&nbsp;the&nbsp;efficacy&nbsp;of&nbsp;two&nbsp;different&nbsp;deferasirox dispersible tablet regimens (starting doses of 5 and 10 mg/kg/day, 55 patients in each arm) and of matching placebo (56 patients). The study enrolled 145 adult and 21 paediatric patients. The primary efficacy parameter was the change in liver iron concentration (LIC) from baseline after 12 months of treatment. One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter. At a starting dose of 10&nbsp;mg/kg/day, deferasirox dispersible tablets led toreductions in indicators of total body iron. On average, liver iron concentration decreased by&nbsp;3.80 mg Fe/g dw in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 0.38 mg Fe/g dw&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;placebo&nbsp;(p&lt;0.001).&nbsp;On&nbsp;average,&nbsp;serum&nbsp;ferritin&nbsp;decreased&nbsp;by&nbsp;222.0 &mu;g/l in&nbsp;patients treated with&nbsp;deferasirox dispersible&nbsp;tablets (starting dose 10&nbsp;mg/kg/day)&nbsp;and increased by 115 &mu;g/l in patients treated with placebo (p&lt;0.001).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Deferasirox film-coated tablets demonstrate higher bioavailability compared to the Deferasirox dispersible tabletformulation. After&nbsp;adjustment of&nbsp;the strength, the&nbsp;film-coated tablet formulation (360 mg strength) was equivalent to Deferasirox dispersible tablets (500 mg&nbsp;strength)&nbsp;with&nbsp;respect&nbsp;to&nbsp;the&nbsp;mean&nbsp;area&nbsp;under&nbsp;the&nbsp;plasma&nbsp;concentrationtime&nbsp;curve&nbsp;(AUC)&nbsp;under fasting conditions. The Cmax&nbsp;was increased by 30% (90% CI: 20.3% - 40.0%);&nbsp;however, a clinical exposure/response analysis revealed no evidence of clinically relevant effects of such an increase.</p><p><u>Absorption</u></p><p>Deferasirox is absorbed following oral administration with a median time to maximum&nbsp;plasma concentration (tmax) of about 1.5 to 4 hours. The absolute bioavailability (AUC) of&nbsp;deferasirox is about 70% compared to an intravenous dose. The absolute bioavailability of the film-coated tablet formulation has not been determined. Bioavailability of deferasirox film-coated tablets was 36% greater than that with dispersible tablets.</p><p>A&nbsp;food-effect&nbsp;study&nbsp;involving&nbsp;administration&nbsp;of&nbsp;the&nbsp;film-coated&nbsp;tablets&nbsp;to&nbsp;healthy&nbsp;volunteers under fasting conditions and with a low-fat (fat content &lt;10% of calories) or high-fat (fat&nbsp;content &gt;50% of calories) meal indicated that the AUC and&nbsp;Cmax&nbsp;were slightly decreased&nbsp;after a low-fat meal (by 11% and 16%, respectively). After a high-fat meal, AUC and Cmax&nbsp;were increased (by 18% and 29%, respectively). The increases in Cmax&nbsp;due to&nbsp;the change in&nbsp;formulation&nbsp;and&nbsp;due&nbsp;to&nbsp;the&nbsp;effect&nbsp;of&nbsp;a&nbsp;high-fat&nbsp;meal&nbsp;may&nbsp;be&nbsp;additive&nbsp;and&nbsp;therefore,&nbsp;it&nbsp;is recommended that the film-coated tablets should be taken either on an empty stomach or&nbsp;with a light meal.</p><p><u>Distribution</u></p><p>Deferasirox&nbsp;is&nbsp;highly (99%)&nbsp;protein&nbsp;bound to plasma&nbsp;proteins,&nbsp;almost&nbsp;exclusively&nbsp;serum albumin, and has a small volume of distribution of approximately 14 litres in adults.</p><p><u>Biotransformation</u></p><p>Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion. Deconjugation of glucuronidates in the intestine and subsequent reabsorption (enterohepatic recycling) is likely to occur: in a healthy volunteer study, the administration of&nbsp;cholestyramine&nbsp;after&nbsp;a&nbsp;single&nbsp;dose&nbsp;of&nbsp;deferasirox&nbsp;resulted&nbsp;in&nbsp;a&nbsp;45%decrease&nbsp;in&nbsp;deferasirox exposure (AUC).</p><p>Deferasirox&nbsp;is&nbsp;mainly&nbsp;glucuronidated&nbsp;by&nbsp;UGT1A1&nbsp;and&nbsp;to&nbsp;a&nbsp;lesser&nbsp;extent&nbsp;UGT1A3.&nbsp;CYP450- catalysed (oxidative) metabolism of&nbsp;deferasirox&nbsp;appears to&nbsp;be&nbsp;minor&nbsp;in&nbsp;humans&nbsp;(about&nbsp;8%). No inhibition of deferasirox metabolism by hydroxyurea was observed&nbsp;<em>in vitro</em>.</p><p><u>Elimination</u></p><p>Deferasirox&nbsp;and&nbsp;its&nbsp;metabolites&nbsp;are&nbsp;primarily&nbsp;excreted&nbsp;in&nbsp;the&nbsp;faeces&nbsp;(84%&nbsp;of&nbsp;the&nbsp;dose).&nbsp;Renal excretion of deferasirox and its metabolites is minimal (8% of the dose). The mean&nbsp;elimination half-life (t1/2) ranged from 8 to 16 hours. The transporters MRP2 and MXR&nbsp;(BCRP) are involved in the biliary excretion of deferasirox.</p><p><u>Linearity&nbsp;/&nbsp;non-linearity</u></p><p>The Cmax&nbsp;and AUC0-24h&nbsp;of deferasirox increase approximately linearly with dose under&nbsp;steady-state&nbsp;conditions.Upon&nbsp;multiple&nbsp;dosing&nbsp;exposure&nbsp;increased&nbsp;by&nbsp;an&nbsp;accumulation&nbsp;factor of 1.3 to 2.3.</p><p><u>Characteristics&nbsp;in&nbsp;patients</u></p><p><em>Paediatric&nbsp;patients</em></p><p>The overall exposure of adolescents (12 to &le;17 years) and children (2 to &lt;12 years) to deferasirox after single and multiple&nbsp;doses was lower than that&nbsp;in&nbsp;adult patients. In children younger than 6 years old exposure was about 50% lower than in adults. Since dosing is individually adjusted according to response this is not expected to have clinical&nbsp;consequences.</p><p><em>Gender</em></p><p>Females have a moderately lower apparent clearance (by 17.5%) for deferasirox compared to males. Since dosing is&nbsp;individually&nbsp;adjusted according to&nbsp;response this is&nbsp;not expected to have clinical consequences.</p><p><em>Elderly&nbsp;patients</em></p><p>The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or&nbsp;older).</p><p><em>Renal&nbsp;or hepatic&nbsp;impairment</em></p><p>The&nbsp;pharmacokinetics&nbsp;of&nbsp;deferasirox&nbsp;have&nbsp;not&nbsp;been&nbsp;studied&nbsp;in&nbsp;patients&nbsp;with&nbsp;renal&nbsp;impairment. The pharmacokinetics of deferasirox&nbsp;were not&nbsp;influenced by liver&nbsp;transaminase levels up to 5 times the upper limit of the normal range.</p><p>In a clinical study using single doses of 20 mg/kg deferasirox, the average exposure was increased by 16% in subjects with mild hepatic impairment (Child-Pugh Class A) and by&nbsp;76% in subjects with moderate hepatic impairment (Child-Pugh Class B) compared to&nbsp;subjects&nbsp;with&nbsp;normal&nbsp;hepatic&nbsp;function.&nbsp;The&nbsp;average&nbsp;Cmax&nbsp;ofdeferasirox&nbsp;in&nbsp;subjects&nbsp;with&nbsp;mild&nbsp;or moderate&nbsp;hepatic impairment was increased by&nbsp;22%. Exposure was increased 2.8-fold in one&nbsp;subject&nbsp;with&nbsp;severe&nbsp;hepatic&nbsp;impairment&nbsp;(Child-Pugh&nbsp;Class&nbsp;C)&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical&nbsp;data&nbsp;reveal&nbsp;no&nbsp;special&nbsp;hazard&nbsp;for&nbsp;humans&nbsp;based&nbsp;on&nbsp;conventional&nbsp;studies&nbsp;of&nbsp;safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential. The main findings&nbsp;were&nbsp;kidney&nbsp;toxicity&nbsp;and&nbsp;lensopacity&nbsp;(cataracts).&nbsp;Similar&nbsp;findings&nbsp;were&nbsp;observed&nbsp;in neonatal and juvenile animals. The kidney toxicity is considered mainly due to iron deprivation in animals that were not previously overloaded with iron.</p><p>Tests&nbsp;of&nbsp;genotoxicity&nbsp;<em>in&nbsp;vitro&nbsp;</em>were&nbsp;negative&nbsp;(Ames&nbsp;test, chromosomal&nbsp;aberration&nbsp;test) while deferasirox caused formation of micronuclei in vivo in the bone marrow, but not liver, of non-iron-loaded rats at lethal doses. No such effects were observed in iron-preloaded rats. Deferasirox&nbsp;was&nbsp;not&nbsp;carcinogenic&nbsp;when&nbsp;administered&nbsp;to&nbsp;rats&nbsp;in&nbsp;a2-year&nbsp;study&nbsp;and&nbsp;transgenic p53+/- heterozygous mice in a 6-month study.</p><p>The potential for toxicity to reproduction was assessed in rats and rabbits. Deferasirox was not teratogenic but caused increased frequency of skeletal variations and stillborn pups in rats at high doses that were severely toxic to the non-iron-overloaded mother. Deferasirox&nbsp;did not cause other effects on fertility or reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline&nbsp;Cellulose</p><p>Croscaramellose Sodium</p><p>Low-substituted&nbsp;Hydroxypropyl&nbsp;cellulose</p><p>Poloxamer 188</p><p>Povidone K 30&nbsp;</p><p>Lactose&nbsp;Monohydrate</p><p>Colloidal Silicon Dioxide</p><p>Sodium stearyl fumarate</p><p>Hydrogenated Castor oil</p><p>Opadry&nbsp;Yellow&nbsp;03H520019</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Keep out of sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 Tablets of FERASIRO 90/180/360 are sealed with Plain Lid Coated Aluminium Foil on one&nbsp;side&nbsp;and&nbsp;clearPVC/PE/PVdC&nbsp;film&nbsp;on&nbsp;another&nbsp;side&nbsp;in&nbsp;the&nbsp;form&nbsp;of&nbsp;a&nbsp;Alu-PVC/PE/PVdC&nbsp;blister pack&nbsp;and&nbsp;such&nbsp;1&nbsp;(1x10)&nbsp;or&nbsp;3&nbsp;(3x10)&nbsp;blisters&nbsp;are&nbsp;further packed&nbsp;in&nbsp;printed carton&nbsp;along with instructions for use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company,
Sudair Industrial Zone,
Sudair,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>